BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362. [PMID: 9090379 DOI: 10.1038/ng0497-356] [Cited by in Crossref: 1854] [Cited by in F6Publishing: 1787] [Article Influence: 74.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Gjörloff-wingren A, Saxena M, Pathan N, Reed JC, Mustelin T. The Tumor Suppressor PTEN Regulates T Cell Survival and Antigen Receptor Signaling by Acting as a Phosphatidylinositol 3-Phosphatase. J Immunol 2000;164:1934-9. [DOI: 10.4049/jimmunol.164.4.1934] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.1] [Reference Citation Analysis]
2 Zhao Y, Wang J, Yang J, Miao J. Synergistic antitumor effect of ING4/PTEN double tumor suppressors mediated by adenovirus modified with arginine-glycine-aspartate on glioma. J Neurosurg Sci 2020;64. [DOI: 10.23736/s0390-5616.17.03978-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Singh B, Ittmann MM, Krolewski JJ. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosom Cancer 1998;21:166-71. [DOI: 10.1002/(sici)1098-2264(199802)21:2<166::aid-gcc13>3.0.co;2-p] [Cited by in Crossref: 53] [Article Influence: 2.2] [Reference Citation Analysis]
4 Allain DC. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2008;10:383-395. [PMID: 18687797 DOI: 10.2353/jmoldx.2008.070161] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
5 Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008;7:1745-62. [PMID: 18594202 DOI: 10.4161/cc.7.12.6166] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
6 Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 2003;3:23. [PMID: 13678425 DOI: 10.1186/1471-2407-3-23] [Cited by in Crossref: 166] [Cited by in F6Publishing: 164] [Article Influence: 8.7] [Reference Citation Analysis]
7 Han KS, Jeong IG, Joung JY, Yang SO, Chung J, Seo HK, Kwon KS, Park WS, Lee KH. Clinical value of PTEN in patients with superficial bladder cancer. Urol Int 2008;80:264-9. [PMID: 18480628 DOI: 10.1159/000127338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
8 Chen M, Yang Y, Liu Y, Chen C. The Role of Chromosome Deletions in Human Cancers. Adv Exp Med Biol 2018;1044:135-48. [PMID: 29956295 DOI: 10.1007/978-981-13-0593-1_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Vidal S, Bouzaher YH, El Motiam A, Seoane R, Rivas C. Overview of the regulation of the class IA PI3K/AKT pathway by SUMO. Semin Cell Dev Biol 2021:S1084-9521(21)00275-5. [PMID: 34753687 DOI: 10.1016/j.semcdb.2021.10.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nakada-Tsukui K, Watanabe N, Maehama T, Nozaki T. Phosphatidylinositol Kinases and Phosphatases in Entamoeba histolytica. Front Cell Infect Microbiol 2019;9:150. [PMID: 31245297 DOI: 10.3389/fcimb.2019.00150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
11 Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Thennarasu K, Chandramouli BA, Hegde AS, Santosh V. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 2011;31:376-83. [PMID: 21134002 DOI: 10.1111/j.1440-1789.2010.01178.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
12 Pendaries C, Tronchère H, Plantavid M, Payrastre B. Phosphoinositide signaling disorders in human diseases. FEBS Letters 2003;546:25-31. [DOI: 10.1016/s0014-5793(03)00437-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
13 Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002;160:795-800. [PMID: 11891178 DOI: 10.1016/S0002-9440(10)64902-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
14 Macoska JA, Xu J, Ziemnicka D, Schwab TS, Rubin MA, Kotula L. Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma. Neoplasia 2001;3:99-104. [PMID: 11420744 DOI: 10.1038/sj.neo.7900145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
15 Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 2007;14:543-9. [PMID: 17431403 DOI: 10.1038/sj.cgt.7701050] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
16 Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Díaz M. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol. 2011;5:265-314. [PMID: 22084619 DOI: 10.4137/cmo.s7685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
17 Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer. 2003;105:625-629. [PMID: 12740910 DOI: 10.1002/ijc.11123] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 3.4] [Reference Citation Analysis]
18 Whang YE, Wu X, Sawyers CL. Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst 1998;90:859-61. [PMID: 9625175 DOI: 10.1093/jnci/90.11.859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
19 Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem 2001;276:11402-8. [PMID: 11278366 DOI: 10.1074/jbc.M007806200] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
20 Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2009;69:7911-6. [PMID: 19808964 DOI: 10.1158/0008-5472.CAN-09-1287] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
21 Abdulkareem IH, Blair M. Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J 2013;54:79-86. [PMID: 23798791 DOI: 10.4103/0300-1652.110033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
22 Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S, Quesenberry PJ, Litofsky NS, Recht LD, Nabi R, Miller SJ, Ohta S, Neel BG, Ross AH. A role for nuclear PTEN in neuronal differentiation. J Neurosci 2000;20:1404-13. [PMID: 10662831 [PMID: 10662831 DOI: 10.1523/jneurosci.20-04-01404.2000] [Cited by in Crossref: 166] [Article Influence: 7.5] [Reference Citation Analysis]
23 Jang HD, Noh JY, Shin JH, Lin JJ, Lee SY. PTEN regulation by the Akt/GSK-3β axis during RANKL signaling. Bone 2013;55:126-31. [DOI: 10.1016/j.bone.2013.02.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
24 Abdullah JM, Farizan A, Asmarina K, Zainuddin N, Ghazali MM, Jaafar H, Isa MN, Naing NN. Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia. Asian J Surg 2006;29:274-82. [PMID: 17098662 DOI: 10.1016/S1015-9584(09)60102-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
25 Eng C. Cowden Syndrome. J Genet Counsel 1997;6:181-92. [DOI: 10.1023/a:1025664119494] [Cited by in Crossref: 81] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
26 Sun W, Zhang DD, Guo L, Wang Q. Expression and significance of hypoxia-inducible factor-1α and its regulator phosphatase and tensin homolog deleted in chromosome 10 in gastric cancer. Shijie Huaren Xiaohua Zazhi 2007; 15(26): 2847-2851 [DOI: 10.11569/wcjd.v15.i26.2847] [Reference Citation Analysis]
27 Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002;33:405-9. [PMID: 12055674 DOI: 10.1053/hupa.2002.124721] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 5.2] [Reference Citation Analysis]
28 Barthel FP, Johnson KC, Wesseling P, Verhaak RGW. Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurol Clin 2018;36:421-37. [PMID: 30072063 DOI: 10.1016/j.ncl.2018.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
29 Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y. PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep 2015;5:17873. [PMID: 26657567 DOI: 10.1038/srep17873] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
30 Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, Whang YE, Stanbridge EJ. Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 2001;21:5846-56. [PMID: 11486024 DOI: 10.1128/MCB.21.17.5846-5856.2001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mita MM, Tolcher AW. The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep 2007;9:316-22. [PMID: 17588357 DOI: 10.1007/s11912-007-0039-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
32 Beg S, Siraj AK, Jehan Z, Prabakaran S, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS. PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. Br J Cancer. 2015;112:1938-1943. [PMID: 25989274 DOI: 10.1038/bjc.2015.169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
33 Moon SK, Kim HM, Kim CH. PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells. Arch Biochem Biophys. 2004;421:267-276. [PMID: 14984207 DOI: 10.1016/j.abb.2003.11.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
34 Yusufu A, Tuerdi R, Redati D, Rehemutula A, Zhao ZL, Wang HJ. Expression and clinical correlation of Survivin and PTEN in gastric cancer patients. Oncol Lett 2020;20:297. [PMID: 33101491 DOI: 10.3892/ol.2020.12160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Sun H, Zhou X, Bao Y, Xiong G, Cui Y, Zhou H. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer. Open Biol 2019;9:180227. [PMID: 31337279 DOI: 10.1098/rsob.180227] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
36 Nagy E, Gajjar KB, Patel II, Taylor S, Martin-Hirsch PL, Stringfellow HF, Martin FL, Phillips DH. MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Br J Cancer 2014;110:2874-80. [PMID: 24853176 DOI: 10.1038/bjc.2014.263] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
37 Cabral-Costa JV, Andreotti DZ, Mello NP, Scavone C, Camandola S, Kawamoto EM. Intermittent fasting uncovers and rescues cognitive phenotypes in PTEN neuronal haploinsufficient mice. Sci Rep 2018;8:8595. [PMID: 29872062 DOI: 10.1038/s41598-018-26814-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
38 Maurice-duelli A, Ndoye A, Bouali S, Leroux A, Merlin J. Enhanced Cell Growth Inhibition following PTEN Nonviral Gene Transfer Using Polyethylenimine and Photochemical Internalization in Endometrial Cancer Cells. Technol Cancer Res Treat 2004;3:459-65. [DOI: 10.1177/153303460400300507] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
39 Gonzalez-Guerrico AM, Meshki J, Xiao L, Benavides F, Conti CJ, Kazanietz MG. Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J Biochem Mol Biol 2005;38:639-45. [PMID: 16336777 DOI: 10.5483/bmbrep.2005.38.6.639] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
40 Paramio JM, Navarro M, Segrelles C, Gómez-casero E, Jorcano JL. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999;18:7462-8. [DOI: 10.1038/sj.onc.1203151] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 3.6] [Reference Citation Analysis]
41 Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 1998;95:13513-8. [PMID: 9811831 DOI: 10.1073/pnas.95.23.13513] [Cited by in Crossref: 818] [Cited by in F6Publishing: 785] [Article Influence: 34.1] [Reference Citation Analysis]
42 Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-106. [PMID: 11395387 DOI: 10.1016/S0002-9440(10)64681-0] [Cited by in Crossref: 177] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
43 Guigon CJ, Cheng SY. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol 2009;308:63-9. [PMID: 19549593 DOI: 10.1016/j.mce.2009.01.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
44 Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst. 2006;98:545-556. [PMID: 16622124 DOI: 10.1093/jnci/djj133] [Cited by in Crossref: 280] [Cited by in F6Publishing: 247] [Article Influence: 17.5] [Reference Citation Analysis]
45 Henderson YC, Wang E, Clayman GL. Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. Laryngoscope 1998;108:1553-6. [PMID: 9778300 DOI: 10.1097/00005537-199810000-00024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
46 Sauvageot CM, Kesari S, Stiles CD. Molecular pathogenesis of adult brain tumors and the role of stem cells. Neurol Clin 2007;25:891-924, vii. [PMID: 17964020 DOI: 10.1016/j.ncl.2007.07.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
47 Xie F, Su M, Qiu W, Zhang M, Guo Z, Su B, Liu J, Li X, Zhou L. Kaempferol promotes apoptosis in human bladder cancer cells by inducing the tumor suppressor, PTEN. Int J Mol Sci 2013;14:21215-26. [PMID: 24284390 DOI: 10.3390/ijms141121215] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
48 Sükösd F, Digon B, Fischer J, Pietsch T, Kovacs G. Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet Cytogenet 2001;128:161-3. [PMID: 11463457 DOI: 10.1016/s0165-4608(01)00413-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
49 Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, Verma IM. Development of a novel mouse glioma model using lentiviral vectors. Nat Med. 2009;15:110-116. [PMID: 19122659 DOI: 10.1038/nm.1863] [Cited by in Crossref: 206] [Cited by in F6Publishing: 197] [Article Influence: 15.8] [Reference Citation Analysis]
50 Stephen RM, Pagel MD, Brown K, Baker AF, Meuillet EJ, Gillies RJ. Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Exp Biol Med (Maywood) 2012;237:1273-80. [PMID: 23239438 DOI: 10.1258/ebm.2012.011326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
51 Baba M, Schmidt LS, Linehan WM. Hereditary Renal Cell Carcinoma. In: Oya M, editor. Renal Cell Carcinoma. Tokyo: Springer Japan; 2017. pp. 19-82. [DOI: 10.1007/978-4-431-55531-5_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Liu J, Chin-Sang ID. C. elegans as a model to study PTEN's regulation and function. Methods 2015;77-78:180-90. [PMID: 25514044 DOI: 10.1016/j.ymeth.2014.12.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
53 Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Terro F. Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A. Ageing Res Rev 2013;12:39-49. [PMID: 22771380 DOI: 10.1016/j.arr.2012.06.008] [Cited by in Crossref: 138] [Cited by in F6Publishing: 119] [Article Influence: 15.3] [Reference Citation Analysis]
54 Xiong Q, Oviedo HV, Trotman LC, Zador AM. PTEN regulation of local and long-range connections in mouse auditory cortex. J Neurosci 2012;32:1643-52. [PMID: 22302806 DOI: 10.1523/JNEUROSCI.4480-11.2012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
55 Lister N, Shevchenko G, Walshe JL, Groen J, Johnsson P, Vidarsdóttir L, Grander D, Ataide SF, Morris KV. The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene. Proc Natl Acad Sci U S A 2017;114:9942-7. [PMID: 28847966 DOI: 10.1073/pnas.1621490114] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
56 Zhang Z, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacology & Therapeutics 2002;93:307-17. [DOI: 10.1016/s0163-7258(02)00199-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
57 Pascual J, Turner N. Targeting the PI3-kinase pathway in triple-negative breast cancer. Annals of Oncology 2019;30:1051-60. [DOI: 10.1093/annonc/mdz133] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
58 Kosmas K, Mitropoulou G, Provatas I, Stamoulas M, Marouga A. Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma. Cytopathology 2018;29:558-64. [PMID: 30007089 DOI: 10.1111/cyt.12612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Wang DY, Xiang YY, Li XJ, Hashimoto M, Tanaka M, Sugimura H. Mxi1 is a potential cellular target of carcinogens and frequently mutated in experimental rat tumors and tumor cell lines. Pathol Int 2000;50:373-83. [PMID: 10849326 DOI: 10.1046/j.1440-1827.2000.01057.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
60 Couto SS, Bolon B, Cardiff RD. Morphologic manifestations of gene-specific molecular alterations ("genetic addictions") in mouse models of disease. Vet Pathol 2012;49:116-29. [PMID: 22173978 DOI: 10.1177/0300985811430962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res. 2007;37:389-396. [PMID: 17441812 DOI: 10.1111/j.1872-034x.2007.00042.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
62 Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, Gersell DJ, Goodfellow PJ. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 2000;79:101-6. [PMID: 11006040 DOI: 10.1006/gyno.2000.5900] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
63 Noguera NI, Song MS, Divona M, Catalano G, Calvo KL, García F, Ottone T, Florenzano F, Faraoni I, Battistini L, Colombo E, Amadori S, Pandolfi PP, Lo-Coco F. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 2013;27:1037-43. [PMID: 23183427 DOI: 10.1038/leu.2012.314] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
64 Meng Y, Cai KQ, Moore R, Tao W, Tse JD, Smith ER, Xu XX. Pten facilitates epiblast epithelial polarization and proamniotic lumen formation in early mouse embryos. Dev Dyn 2017;246:517-30. [PMID: 28387983 DOI: 10.1002/dvdy.24503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
65 Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009;36 Suppl 3:S3-S17. [PMID: 19963098 DOI: 10.1053/j.seminoncol.2009.10.011] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 12.3] [Reference Citation Analysis]
66 Tang X, Powelka AM, Soriano NA, Czech MP, Guilherme A. PTEN, but Not SHIP2, Suppresses Insulin Signaling through the Phosphatidylinositol 3-Kinase/Akt Pathway in 3T3-L1 Adipocytes. Journal of Biological Chemistry 2005;280:22523-9. [DOI: 10.1074/jbc.m501949200] [Cited by in Crossref: 82] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
67 Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997;16:333-334. [PMID: 9241266 DOI: 10.1038/ng0897-333] [Cited by in Crossref: 423] [Cited by in F6Publishing: 389] [Article Influence: 16.9] [Reference Citation Analysis]
68 Omori N, Jin G, Li F, Zhang W, Wang S, Hamakawa Y, Nagano I, Manabe Y, Shoji M, Abe K. Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Research 2002;954:317-22. [DOI: 10.1016/s0006-8993(02)03366-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
69 Li B, Smith TJ. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN. J Clin Endocrinol Metab 2014;99:3363-72. [PMID: 24840811 DOI: 10.1210/jc.2014-1257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
70 Bellizzi AM, Bloomston M, Zhou X, Iwenofu OH, Frankel WL. The mTOR Pathway is Frequently Activated in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Applied Immunohistochemistry & Molecular Morphology 2010;18:442-7. [DOI: 10.1097/pai.0b013e3181de115b] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
71 Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011;10:481-90. [PMID: 21538076 DOI: 10.1007/s10689-011-9446-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
72 Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013;32:1155-63. [PMID: 22580610 DOI: 10.1038/onc.2012.132] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
73 Park NI, Rogan PK, Tarnowski HE, Knoll JH. Structural and genic characterization of stable genomic regions in breast cancer: relevance to chemotherapy. Mol Oncol 2012;6:347-59. [PMID: 22342187 DOI: 10.1016/j.molonc.2012.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
74 Rasool S, Rasool V, Naqvi T, Ganai BA, Shah BA. Genetic unraveling of colorectal cancer. Tumour Biol. 2014;35:5067-5082. [PMID: 24573608 DOI: 10.1007/s13277-014-1713-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
75 Liang T, Gao F, Chen J. Role of PTEN-less in cardiac injury, hypertrophy and regeneration. Cell Regen 2021;10:25. [PMID: 34337686 DOI: 10.1186/s13619-021-00087-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Sandell S, Schuit RJ, Bunyan DJ. An intronic polymorphic deletion in the PTEN gene: implications for molecular diagnostic testing. Br J Cancer 2013;108:438-41. [PMID: 23299532 DOI: 10.1038/bjc.2012.562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
77 Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, Gazdar AF. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-19. [PMID: 9559342 DOI: 10.1002/(sici)1098-2264(199804)21:4<308::aid-gcc4>3.0.co;2-2] [Cited by in Crossref: 119] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
78 Pollack IF, Hamilton RL, Finkelstein SD, Lieberman F. Molecular abnormalities and correlations with tumor response and outcome in glioma patients. Neuroimaging Clinics of North America 2002;12:627-39. [DOI: 10.1016/s1052-5149(02)00030-8] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
79 Hu Y, An Y, Fang N, Li Y, Jin H, Nazarali A, Ji S. The Optimization of Soluble PTEN Expression in Escherichia coli. Open Biochem J 2015;9:42-8. [PMID: 26464590 DOI: 10.2174/1874091X01509010042] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
80 Labbé DP, Hardy S, Tremblay ML. Protein tyrosine phosphatases in cancer: friends and foes! Prog Mol Biol Transl Sci. 2012;106:253-306. [PMID: 22340721 DOI: 10.1016/B978-0-12-396456-4.00009-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
81 Ren W, Duan Y, Yang Y, Ji Y, Chen F. Down-regulation of Stat3 induces apoptosis of human glioma cell: a potential method to treat brain cancer. Neurol Res 2008;30:297-301. [PMID: 17716392 DOI: 10.1179/016164107X230784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
82 Chen L, Guo D. The functions of tumor suppressor PTEN in innate and adaptive immunity. Cell Mol Immunol 2017;14:581-9. [PMID: 28603282 DOI: 10.1038/cmi.2017.30] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
83 Zhu Y, Hoell P, Ahlemeyer B, Sure U, Bertalanffy H, Krieglstein J. Implication of PTEN in production of reactive oxygen species and neuronal death in in vitro models of stroke and Parkinson's disease. Neurochem Int 2007;50:507-16. [PMID: 17169462 DOI: 10.1016/j.neuint.2006.10.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
84 Belletti B, Prisco M, Morrione A, Valentinis B, Navarro M, Baserga R. Regulation of Id2 gene expression by the insulin-like growth factor I receptor requires signaling by phosphatidylinositol 3-kinase. J Biol Chem 2001;276:13867-74. [PMID: 11278691 DOI: 10.1074/jbc.M010509200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
85 Strahl T, Thorner J. Synthesis and function of membrane phosphoinositides in budding yeast, Saccharomyces cerevisiae. Biochim Biophys Acta 2007;1771:353-404. [PMID: 17382260 DOI: 10.1016/j.bbalip.2007.01.015] [Cited by in Crossref: 204] [Cited by in F6Publishing: 198] [Article Influence: 13.6] [Reference Citation Analysis]
86 Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 2016;22:2874-84. [PMID: 26787751 DOI: 10.1158/1078-0432.CCR-15-2225] [Cited by in Crossref: 65] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
87 Liu Z, Ke F, Duan C, Lan H, Li J, Gao C, Li J, Zhong Z. Mannan-conjugated adenovirus enhanced gene therapy effects on murine hepatocellular carcinoma cells in vitro and in vivo. Bioconjug Chem 2013;24:1387-97. [PMID: 23937094 DOI: 10.1021/bc400215a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
88 Tsuda H, Takarabe T, Okada S, Uchida H, Kasamatsu T, Yamada T, Tsunematsu R, Ohmi K, Hirohashi S. Different pattern of loss of heterozygosity among endocervical-type adenocarcinoma, endometrioid-type adenocarcinoma and adenoma malignum of the uterine cervix. Int J Cancer 2002;98:713-7. [DOI: 10.1002/ijc.10228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
89 Li G, Hu Y, Huo Y, Liu M, Freeman D, Gao J, Liu X, Wu DC, Wu H. PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J Biol Chem 2006;281:10663-8. [PMID: 16507572 DOI: 10.1074/jbc.M512509200] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
90 Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y, Liu Y. Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer. Biomed Rep 2014;2:653-8. [PMID: 25054006 DOI: 10.3892/br.2014.298] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
91 Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 2008;28:3281-9. [PMID: 18332125 DOI: 10.1128/MCB.00310-08] [Cited by in Crossref: 97] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
92 Seltzer S, Corrigan M, O'Reilly S. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer. Exp Mol Pathol 2020;114:104404. [PMID: 32067942 DOI: 10.1016/j.yexmp.2020.104404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
93 Hwang PH, Yi HK, Kim DS, Nam SY, Kim JS, Lee DY. Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett. 2001;172:83-91. [PMID: 11595133 DOI: 10.1016/s0304-3835(01)00632-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
94 Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, Depinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 2006;9:379-90. [DOI: 10.1016/j.ccr.2006.03.028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
95 Yehia L, Ngeow J, Eng C. PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest 2019;129:452-64. [PMID: 30614812 DOI: 10.1172/JCI121277] [Cited by in Crossref: 64] [Cited by in F6Publishing: 37] [Article Influence: 21.3] [Reference Citation Analysis]
96 Hosoya Y, Gemma A, Seike M, Kurimoto F, Uematsu K, Hibino S, Yoshimura A, Shibuya M, Kudoh S. Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer. 1999;25:87-93. [PMID: 10470842 DOI: 10.1016/s0169-5002(99)00052-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
97 Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nat Commun 2016;7:13719. [PMID: 27941799 DOI: 10.1038/ncomms13719] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
98 Braud A, de Rocquancourt A, Marty M, Espie M. Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: Report of two patients. Annals of Oncology 1999;10:1241-3. [DOI: 10.1023/a:1008317923860] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res 2011;71:629-33. [PMID: 21266353 DOI: 10.1158/0008-5472.CAN-10-2488] [Cited by in Crossref: 172] [Cited by in F6Publishing: 94] [Article Influence: 15.6] [Reference Citation Analysis]
100 Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS, Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene. 2002;21:5289-5300. [PMID: 12149650 DOI: 10.1038/sj.onc.1205650] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 3.5] [Reference Citation Analysis]
101 Ghafouri-Fard S, Abak A, Shoorei H, Mohaqiq M, Majidpoor J, Sayad A, Taheri M. Regulatory role of microRNAs on PTEN signaling. Biomed Pharmacother 2021;133:110986. [PMID: 33166764 DOI: 10.1016/j.biopha.2020.110986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
102 Davies EM, Sheffield DA, Tibarewal P, Fedele CG, Mitchell CA, Leslie NR. The PTEN and Myotubularin Phosphoinositide 3-Phosphatases: Linking Lipid Signalling to Human Disease. In: Balla T, Wymann M, York JD, editors. Phosphoinositides I: Enzymes of Synthesis and Degradation. Dordrecht: Springer Netherlands; 2012. pp. 281-336. [DOI: 10.1007/978-94-007-3012-0_8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
103 Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, Shirai M, Kubota N. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 2005;96:911-7. [PMID: 16367912 DOI: 10.1111/j.1349-7006.2005.00125.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
104 Yang YC, Ho TC, Chen SL, Lai HY, Wu JY, Tsao YP. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. BMC Cancer 2007;7:216. [PMID: 18021457 DOI: 10.1186/1471-2407-7-216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
105 Brandmaier A, Hou SQ, Demaria S, Formenti SC, Shen WH. PTEN at the interface of immune tolerance and tumor suppression. Front Biol (Beijing) 2017;12:163-74. [PMID: 29527223 DOI: 10.1007/s11515-017-1443-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
106 Diaz-Meco MT, Abu-Baker S. The Par-4/PTEN connection in tumor suppression. Cell Cycle 2009;8:2518-22. [PMID: 19625770 DOI: 10.4161/cc.8.16.9384] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
107 Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 1999;155:387-94. [PMID: 10433932 DOI: 10.1016/S0002-9440(10)65135-8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
108 Corbalán-García S, Gómez-Fernández JC. Protein kinase C regulatory domains: the art of decoding many different signals in membranes. Biochim Biophys Acta 2006;1761:633-54. [PMID: 16809062 DOI: 10.1016/j.bbalip.2006.04.015] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 5.9] [Reference Citation Analysis]
109 Wang H, Zhang P, Lin C, Yu Q, Wu J, Wang L, Cui Y, Wang K, Gao Z, Li H. Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma. PLoS One 2015;10:e114250. [PMID: 25714556 DOI: 10.1371/journal.pone.0114250] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
110 Georgescu MM, Li Y, Islam MZ, Notarianni C, Sun H, Olar A, Fuller GN. Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications. Oncotarget 2019;10:4038-52. [PMID: 31258848 DOI: 10.18632/oncotarget.27005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
111 Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. J Biol Chem 2006;281:26562-8. [PMID: 16829519 DOI: 10.1074/jbc.M605391200] [Cited by in Crossref: 141] [Cited by in F6Publishing: 81] [Article Influence: 8.8] [Reference Citation Analysis]
112 Ming M, He YY. PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol 2009;129:2109-12. [PMID: 19340009 DOI: 10.1038/jid.2009.79] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
113 Lotan TL, Torres A, Zhang M, Tosoian JJ, Guedes LB, Fedor H, Hicks J, Ewing CM, Isaacs SD, Johng D, De Marzo AM, Isaacs WB. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget 2017;8:22772-82. [PMID: 28186998 DOI: 10.18632/oncotarget.15196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
114 Pollock PM, Walker GJ, Glendening JM, Que Noy T, Bloch NC, Fountain JW, Hayward NK. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines: . Melanoma Research 2002;12:565-75. [DOI: 10.1097/00008390-200212000-00006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
115 Wang X, Fan Y, Du Z, Fan J, Hao Y, Wang J, Wu X, Luo C. Knockdown of Phospholipase Cε (PLCε) Inhibits Cell Proliferation via Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)/AKT Signaling Pathway in Human Prostate Cancer. Med Sci Monit 2018;24:254-63. [PMID: 29330357 DOI: 10.12659/msm.908109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Murakami Y, Sekiya T. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1998;400:421-37. [DOI: 10.1016/s0027-5107(98)00031-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
117 Uppal S, Mistry D, Coatesworth AP. Cowden disease: a review: Cowden disease. International Journal of Clinical Practice 2007;61:645-52. [DOI: 10.1111/j.1742-1241.2006.00896.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
118 Hu PJ, Xu J, Ruvkun G. Two membrane-associated tyrosine phosphatase homologs potentiate C. elegans AKT-1/PKB signaling. PLoS Genet 2006;2:e99. [PMID: 16839187 DOI: 10.1371/journal.pgen.0020099] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
119 Ali-osman F. Brain Tumors. In: Masters JRW, Palsson B, editors. Human Cell Culture. Dordrecht: Kluwer Academic Publishers; 2002. pp. 167-84. [DOI: 10.1007/0-306-46861-1_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res. 2012;2012:659649. [PMID: 22121480 DOI: 10.1155/2012/659649] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
121 Kohno T, Kawanishi M, Matsuda S, Ichikawa H, Takada M, Ohki M, Yamamoto T, Yokota J. Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including theANA gene in human lung carcinoma. Genes Chromosom Cancer 1998;21:236-43. [DOI: 10.1002/(sici)1098-2264(199803)21:3<236::aid-gcc8>3.0.co;2-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
122 Chen X, Liu B, Li Q, Honorio S, Liu X, Liu C, Multani AS, Calhoun-Davis T, Tang DG. Dissociated primary human prostate cancer cells coinjected with the immortalized Hs5 bone marrow stromal cells generate undifferentiated tumors in NOD/SCID-γ mice. PLoS One 2013;8:e56903. [PMID: 23451107 DOI: 10.1371/journal.pone.0056903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
123 Robinson S, Cohen AR. Cowden Disease and Lhermitte-Duclos Disease: Characterization of a New Phakomatosis. Neurosurgery 2000;46:371-371. [DOI: 10.1097/00006123-200002000-00021] [Cited by in Crossref: 67] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
124 Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006;17:1120-7. [PMID: 16600976 DOI: 10.1093/annonc/mdl077] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 4.5] [Reference Citation Analysis]
125 Shiraishi T, Tabuchi K. Genetic alterations of human brain tumors as molecular prognostic factors. Neuropathology 2003;23:95-108. [DOI: 10.1046/j.1440-1789.2003.00477.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
126 Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 2000;97:3207-3212. [PMID: 10716737 DOI: 10.1073/pnas.060579697] [Cited by in Crossref: 64] [Cited by in F6Publishing: 137] [Article Influence: 2.9] [Reference Citation Analysis]
127 Moritake H, Horii Y, Kuroda H, Sugimoto T. Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Genet Cytogenet 2001;125:151-5. [PMID: 11369059 DOI: 10.1016/s0165-4608(00)00378-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
128 Wang C, Ma J, Zhang N, Yang Q, Jin Y, Wang Y. The acetyl-CoA carboxylase enzyme: a target for cancer therapy? Expert Rev Anticancer Ther 2015;15:667-76. [PMID: 25979092 DOI: 10.1586/14737140.2015.1038246] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
129 Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA. 1999;96:1563-1568. [PMID: 9990064 DOI: 10.1073/pnas.96.4.1563] [Cited by in Crossref: 708] [Cited by in F6Publishing: 653] [Article Influence: 30.8] [Reference Citation Analysis]
130 Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN Gene Alterations in Lymphoid Neoplasms. Blood 1998;92:3410-5. [DOI: 10.1182/blood.v92.9.3410.421a06_3410_3415] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
131 Grønbæk K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-jensen K, Guldberg P. Somatic Fas Mutations in Non-Hodgkin’s Lymphoma: Association With Extranodal Disease and Autoimmunity. Blood 1998;92:3018-24. [DOI: 10.1182/blood.v92.9.3018] [Cited by in Crossref: 222] [Article Influence: 9.3] [Reference Citation Analysis]
132 Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 2010;70:453-62. [PMID: 20068170 DOI: 10.1158/0008-5472.CAN-09-2189] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
133 C. Zapico S, Menéndez ST, Núñez P. Cell death proteins as markers of early postmortem interval. Cell Mol Life Sci 2014;71:2957-62. [DOI: 10.1007/s00018-013-1531-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
134 Ghosh AK, Grigorieva I, Steele R, Hoover RG, Ray RB. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. Gene. 1999;235:85-91. [PMID: 10415336 DOI: 10.1016/s0378-1119(99)00206-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
135 Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74. [PMID: 16288293 DOI: 10.1038/sj.onc.1209096] [Cited by in Crossref: 241] [Cited by in F6Publishing: 224] [Article Influence: 14.2] [Reference Citation Analysis]
136 Laxmi A, Gupta P, Gupta J. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target. CBM 2019;24:383-93. [DOI: 10.3233/cbm-181601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Antal CE, Newton AC. Spatiotemporal dynamics of phosphorylation in lipid second messenger signaling. Mol Cell Proteomics 2013;12:3498-508. [PMID: 23788531 DOI: 10.1074/mcp.R113.029819] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
138 Hang Y, Zheng YC, Cao Y, Li QS, Sui YJ. Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J Gastroenterol 2005; 11(15): 2224-2229 [PMID: 15818730 DOI: 10.3748/wjg.v11.i15.2224] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
139 Khan I, Ansari IA, Singh P, Dass J FP. Prediction of functionally significant single nucleotide polymorphisms in PTEN tumor suppressor gene: An in silico approach. Biotechnol Appl Biochem 2017;64:657-66. [PMID: 26800850 DOI: 10.1002/bab.1483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
140 Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol 2004;273:175-84. [PMID: 15328005 DOI: 10.1016/j.ydbio.2004.06.008] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 9.3] [Reference Citation Analysis]
141 Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17:1331-40. [PMID: 21266528 DOI: 10.1158/1078-0432.CCR-10-0540] [Cited by in Crossref: 169] [Cited by in F6Publishing: 99] [Article Influence: 15.4] [Reference Citation Analysis]
142 Knillová J, Kolář Z, Hlobilková A. THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. II. PRODUCTS OF SUPPRESSOR GENES RB AND PTEN, CDKI, FAS. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:11-7. [DOI: 10.5507/bp.2003.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
143 Di Loreto C, Tell G, Pestrin M, Pandolfi M, Damante G, Puglisi F. PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 2005;224:105-9. [PMID: 15911105 DOI: 10.1016/j.canlet.2004.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
144 Vijayakrishnapillai LMK, Desmarais JS, Groeschen MN, Perlin MH. Deletion of ptn1, a PTEN/TEP1 Orthologue, in Ustilago maydis Reduces Pathogenicity and Teliospore Development. J Fungi (Basel) 2018;5:E1. [PMID: 30577430 DOI: 10.3390/jof5010001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
145 Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, Nakamura T, Murata Y. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001;115:32-8. [PMID: 11190805 DOI: 10.1309/7JX6-B9U9-3P0R-EQNY] [Cited by in Crossref: 84] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
146 Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA. 1999;96:10182-10187. [PMID: 10468583 DOI: 10.1073/pnas.96.18.10182] [Cited by in Crossref: 219] [Cited by in F6Publishing: 229] [Article Influence: 9.5] [Reference Citation Analysis]
147 Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8:1169-1178. [PMID: 9799734 DOI: 10.1016/s0960-9822(07)00488-5] [Cited by in Crossref: 555] [Cited by in F6Publishing: 265] [Article Influence: 23.1] [Reference Citation Analysis]
148 Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 2012;341:859-72. [PMID: 22393246 DOI: 10.1124/jpet.112.191536] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
149 Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers (Basel) 2019;11:E1076. [PMID: 31366089 DOI: 10.3390/cancers11081076] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
150 Kang Y, Lee HS, Kim WH. Promoter Methylation and Silencing of PTEN in Gastric Carcinoma. Lab Invest 2002;82:285-91. [DOI: 10.1038/labinvest.3780422] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 7.4] [Reference Citation Analysis]
151 Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453. [PMID: 17456751 DOI: 10.2353/ajpath.2007.070011] [Cited by in Crossref: 895] [Cited by in F6Publishing: 790] [Article Influence: 59.7] [Reference Citation Analysis]
152 Li L, Ernsting BR, Wishart MJ, Lohse DL, Dixon JE. A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast. Journal of Biological Chemistry 1997;272:29403-6. [DOI: 10.1074/jbc.272.47.29403] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 4.4] [Reference Citation Analysis]
153 Zhang B, Cao J, Zhou Q, Chen JY, Zou XP. Correlation between PTEN protein expression and clinicopathological features in the precancerous lesions and early gastric cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(32): 3626-3630 [DOI: 10.11569/wcjd.v16.i32.3626] [Reference Citation Analysis]
154 Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013;341:395-9. [PMID: 23888040 DOI: 10.1126/science.1236188] [Cited by in Crossref: 256] [Cited by in F6Publishing: 253] [Article Influence: 28.4] [Reference Citation Analysis]
155 De Vivo I, Cui X, Domen J, Cleary ML. Growth stimulation of primary B cell precursors by the anti-phosphatase Sbf1. Proc Natl Acad Sci U S A 1998;95:9471-6. [PMID: 9689104 DOI: 10.1073/pnas.95.16.9471] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
156 Bridges D, Saltiel AR. Phosphoinositides: Key modulators of energy metabolism. Biochim Biophys Acta 2015;1851:857-66. [PMID: 25463477 DOI: 10.1016/j.bbalip.2014.11.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
157 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol 2012;355:135-69. [PMID: 22015553 DOI: 10.1007/82_2011_178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
158 Hensley PJ, Kyprianou N. Modeling prostate cancer in mice: limitations and opportunities. J Androl 2012;33:133-44. [PMID: 21680808 DOI: 10.2164/jandrol.111.013987] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
159 Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res 2014;20:3057-63. [PMID: 24928944 DOI: 10.1158/1078-0432.CCR-12-3680] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
160 Caillet-Saguy C, Maisonneuve P, Delhommel F, Terrien E, Babault N, Lafon M, Cordier F, Wolff N. Strategies to interfere with PDZ-mediated interactions in neurons: What we can learn from the rabies virus. Prog Biophys Mol Biol 2015;119:53-9. [PMID: 25748547 DOI: 10.1016/j.pbiomolbio.2015.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
161 Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 2001;276:27740-4. [PMID: 11356844 DOI: 10.1074/jbc.M102559200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
162 Ehrlich M, Bacharach E. Oncolytic Virotherapy: The Cancer Cell Side. Cancers (Basel) 2021;13:939. [PMID: 33668131 DOI: 10.3390/cancers13050939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 2010;18:371-4. [PMID: 20216404 DOI: 10.1097/PAI.0b013e3181d50bd5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
164 Abdulkadir SA, Kim J. Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility. Future Oncology 2005;1:351-60. [DOI: 10.1517/14796694.1.3.351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
165 Mehenni H, Gehrig C, Nezu J, Oku A, Shimane M, Rossier C, Guex N, Blouin JL, Scott HS, Antonarakis SE. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998;63:1641-50. [PMID: 9837816 DOI: 10.1086/302159] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 5.6] [Reference Citation Analysis]
166 Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-8. [PMID: 10866658 DOI: 10.1128/MCB.20.14.5010-5018.2000] [Cited by in Crossref: 548] [Cited by in F6Publishing: 281] [Article Influence: 24.9] [Reference Citation Analysis]
167 Figer A, Kaplan A, Frydman M, Lev D, Paswell J, Papa MZ, Goldman B, Friedman E. Germline mutations in the PTEN gene in Israeli patients with Bannayan-Riley-Ruvalcaba syndrome and women with familial breast cancer. Clin Genet 2002;62:298-302. [PMID: 12372056 DOI: 10.1034/j.1399-0004.2002.620407.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
168 Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA. 1998;95:9418-9423. [PMID: 9689095 DOI: 10.1073/pnas.95.16.9418] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 2.7] [Reference Citation Analysis]
169 Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y, Xing G, Kong X, Wang L, Li Y, Zhou T, Gao D, Xiao ZX, Yin Y, Wei W, He F, Zhang L. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol 2015;17:1169-81. [PMID: 26280536 DOI: 10.1038/ncb3218] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
170 Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A 2008;105:5396-401. [PMID: 18385383 DOI: 10.1073/pnas.0705410105] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
171 Zhu Y, Shi L, Chen P, Zhang Y, Zhu T. Identification of six candidate genes for endometrial carcinoma by bioinformatics analysis. World J Surg Oncol 2020;18:161. [PMID: 32641130 DOI: 10.1186/s12957-020-01920-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
172 Mueller WC, von Deimling A. Gene Regulation by Methylation. In: von Deimling A, editor. Gliomas. Berlin: Springer Berlin Heidelberg; 2009. pp. 217-39. [DOI: 10.1007/978-3-540-31206-2_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
173 Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 2009;302:276-89. [PMID: 19602687 DOI: 10.1001/jama.2009.1022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
174 Ding X, Morrison G, Dean B, Hop CE, Tobler L, Percey S, Meng M, Reuschel S, West DA, Holden S, Ware JA. A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development. J Pharm Biomed Anal 2012;61:1-7. [PMID: 22169467 DOI: 10.1016/j.jpba.2011.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
175 Chen Y, Chen CF, Polci R, Wei R, Riley DJ, Chen PL. Increased Nek1 expression in renal cell carcinoma cells is associated with decreased sensitivity to DNA-damaging treatment. Oncotarget 2014;5:4283-94. [PMID: 24970796 DOI: 10.18632/oncotarget.2005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
176 Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G. The regulatory roles of phosphatases in cancer. Oncogene. 2014;33:939-953. [PMID: 23503460 DOI: 10.1038/onc.2013.80] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
177 Lee C, Kim JS, Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 2004;64:6906-14. [PMID: 15466180 DOI: 10.1158/0008-5472.CAN-04-1767] [Cited by in Crossref: 74] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
178 Hu YC, Lam KY, Tang JC, Srivastava G. Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol 1999;52:353-6. [PMID: 10748870 DOI: 10.1136/mp.52.6.353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
179 Marsh DJ, Dahia PL, Caron S, Kum JB, Frayling IM, Tomlinson IP, Hughes KS, Eeles RA, Hodgson SV, Murday VA. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 1998;35:881-885. [PMID: 9832031 DOI: 10.1136/jmg.35.11.881] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 4.4] [Reference Citation Analysis]
180 Wang Z, Li Y, Wu D, Yu S, Wang Y, Leung Chan F. Nuclear receptor HNF4α performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence. Oncogene 2020;39:1572-89. [PMID: 31695151 DOI: 10.1038/s41388-019-1080-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
181 Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM, Whiteman DC, Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G; Australian Cancer Study., Breast Cancer Family Registries (BCFR)., Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab). Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009;85:427-46. [PMID: 19781682 DOI: 10.1016/j.ajhg.2009.08.018] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 10.2] [Reference Citation Analysis]
182 Mavros A, Hahn M, Wieland I, Koy S, Koufaki ON, Strelocke K, Koch R, Haroske G, Schackert HK, Eckelt U. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity: Genetic alterations of PTEN/MMAC1 in oral cancer. Journal of Oral Pathology & Medicine 2002;31:270-6. [DOI: 10.1034/j.1600-0714.2002.310504.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
183 Choorapoikayil S, Kuiper RV, de Bruin A, den Hertog J. Haploinsufficiency of the genes encoding the tumor suppressor Pten predisposes zebrafish to hemangiosarcoma. Dis Model Mech 2012;5:241-7. [PMID: 22071262 DOI: 10.1242/dmm.008326] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
184 Depowski PL, Rosenthal SI, Ross JS. Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer. Mod Pathol 2001;14:672-6. [DOI: 10.1038/modpathol.3880371] [Cited by in Crossref: 190] [Cited by in F6Publishing: 186] [Article Influence: 9.0] [Reference Citation Analysis]
185 Dos Anjos Pultz B, da Luz FA, de Faria PR, Oliveira AP, de Araújo RA, Silva MJ. Far beyond the usual biomarkers in breast cancer: a review. J Cancer 2014;5:559-71. [PMID: 25057307 DOI: 10.7150/jca.8925] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
186 Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 2002;21:2357-2364. [PMID: 11948419 DOI: 10.1038/sj.onc.1205296] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
187 Goldberg EK, Glendening JM, Karanjawala Z, Sridhar A, Walker GJ, Hayward NK, Rice AJ, Kurera D, Tebha Y, Fountain JW. Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet 2000;67:417-31. [PMID: 10877980 DOI: 10.1086/302999] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]
188 Achary PM, Zhao H, Fan Z, Gogineni S, Pulijaal VR, Herbst L, Mahadevia PS, Jones JG, Klinger HP, Vikram B. A candidate metastasis-associated DNA marker for ductal mammary carcinoma. Breast Cancer Res 2003;5:R52-8. [PMID: 12631399 DOI: 10.1186/bcr571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
189 Welcsh PL, Schubert EL, King M. Inherited breast cancer: an emerging picture. Clinical Genetics 1998;54:447-58. [DOI: 10.1111/j.1399-0004.1998.tb03764.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
190 van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71-88. [PMID: 21336636 DOI: 10.1007/s13402-011-0010-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
191 Vega A, Torres J, Torres M, Cameselle-Teijeiro J, Macia M, Carracedo A, Pulido R. A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease. J Invest Dermatol. 2003;121:1356-1359. [PMID: 14675182 DOI: 10.1111/j.1523-1747.2003.12638.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
192 Papa A, Pandolfi PP. The PTEN⁻PI3K Axis in Cancer. Biomolecules 2019;9:E153. [PMID: 30999672 DOI: 10.3390/biom9040153] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 21.3] [Reference Citation Analysis]
193 Bi L, Yan X, Yang Y, Qian L, Tian Y, Mao JH, Chen W. The component formula of Salvia miltiorrhiza and Panax ginseng induces apoptosis and inhibits cell invasion and migration through targeting PTEN in lung cancer cells. Oncotarget. 2017;8:101599-101613. [PMID: 29254189 DOI: 10.18632/oncotarget.21354] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
194 Kim JH, Han SY, Lee SW, Baek YH, Kim HY, Kim JH, Jeong JS, Roh YH, Kim YH, Park BH, Kwon HJ, Cho JH, Nam KJ. Sodium iodide symporter and phosphatase and tensin homolog deleted on chromosome ten expression in cholangiocarcinoma analysis with clinicopathological parameters. Gut Liver 2012;6:374-80. [PMID: 22844568 DOI: 10.5009/gnl.2012.6.3.374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
195 López-Otín C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998;19:365-396. [PMID: 9715372 DOI: 10.1210/edrv.19.4.0337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 0.1] [Reference Citation Analysis]
196 van Duijn PW, Trapman J. PI3K/Akt signaling regulates p27kip1 expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27kip1 regulation in LNCaP and PC346 cells. Prostate 2006;66:749-60. [DOI: 10.1002/pros.20398] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
197 Zhang S, Taghibiglou C, Girling K, Dong Z, Lin SZ, Lee W, Shyu WC, Wang YT. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. J Neurosci 2013;33:7997-8008. [PMID: 23637190 DOI: 10.1523/JNEUROSCI.5661-12.2013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
198 Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014;15:65-79. [PMID: 24387334 DOI: 10.2174/1389450114666140106100909] [Cited by in Crossref: 140] [Cited by in F6Publishing: 125] [Article Influence: 17.5] [Reference Citation Analysis]
199 van Gisbergen PA, Li M, Wu SZ, Bezanilla M. Class II formin targeting to the cell cortex by binding PI(3,5)P(2) is essential for polarized growth. J Cell Biol 2012;198:235-50. [PMID: 22801781 DOI: 10.1083/jcb.201112085] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
200 Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56. [PMID: 11504770 DOI: 10.1093/jnci/93.16.1246] [Cited by in Crossref: 409] [Cited by in F6Publishing: 353] [Article Influence: 19.5] [Reference Citation Analysis]
201 Üner AH, Sağlam A, Han Ü, Hayran M, Sungur A, Ruacan Ş. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leukemia & Lymphoma 2009;46:1463-70. [DOI: 10.1080/10428190500144813] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
202 Wan X, Yokoyama Y, Shinohara A, Takahashi Y, Tamaya T. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ 2002;9:414-20. [DOI: 10.1038/sj.cdd.4400982] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
203 Chung RY, Chiocca EA. Gene Therapy for Tumors of the Central Nervous System. Surgical Oncology Clinics of North America 1998;7:589-602. [DOI: 10.1016/s1055-3207(18)30262-x] [Cited by in Crossref: 15] [Article Influence: 0.6] [Reference Citation Analysis]
204 Kuhn E, Ragazzi M, Ciarrocchi A, Torricelli F, de Biase D, Zanetti E, Bisagni A, Corrado S, Uccella S, La Rosa S, Bongiovanni M, Losito S, Piana S. Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study. Mod Pathol 2019;32:787-98. [PMID: 30723294 DOI: 10.1038/s41379-018-0199-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
205 Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai W, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-cordova E, Thompson TC, Butler EB. Expanding the Therapeutic Index of Radiation Therapy by Combining In Situ Gene Therapy in the Treatment of Prostate Cancer. Technol Cancer Res Treat 2006;5:23-36. [DOI: 10.1177/153303460600500104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
206 Yamamoto N, Mizoe J, Numasawa H, Tsujii H, Shibahara T, Noma H. Allelic loss on chromosomes 2q, 3p and 21q: possibly a poor prognostic factor in oral squamous cell carcinoma. Oral Oncology 2003;39:796-805. [DOI: 10.1016/s1368-8375(03)00079-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
207 Yakubov E, Ghoochani A, Buslei R, Buchfelder M, Eyüpoglu IY, Savaskan N. Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency. Oncoscience 2016;3:149-55. [PMID: 27489861 DOI: 10.18632/oncoscience.305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
208 Ma N, Jin J, Lu F, Woodgett J, Liu F. The role of protein kinase B (PKB) in modulating heat sensitivity in a human breast cancer cell line. International Journal of Radiation Oncology*Biology*Physics 2001;50:1041-50. [DOI: 10.1016/s0360-3016(01)01596-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
209 Parkman GL, Foth M, Kircher DA, Holmen SL, McMahon M. The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. Exp Dermatol 2021. [PMID: 34717019 DOI: 10.1111/exd.14489] [Reference Citation Analysis]
210 Xi Y, Chen Y. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies: PTENLOSS IN BONE MALIGNANCIES. J Cell Biochem 2015;116:1837-47. [DOI: 10.1002/jcb.25159] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
211 Mishra RR, Chaudhary JK, Bajaj GD, Rath PC. A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells. PLoS One 2011;6:e28433. [PMID: 22164291 DOI: 10.1371/journal.pone.0028433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
212 Bretón-Romero R, Kalwa H, Lamas S, Michel T. Role of PTEN in modulation of ADP-dependent signaling pathways in vascular endothelial cells. Biochim Biophys Acta 2013;1833:2586-95. [PMID: 23806663 DOI: 10.1016/j.bbamcr.2013.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
213 Haddadi N, Travis G, Nassif NT, Simpson AM, Marsh DJ. Toward Systems Pathology for PTEN Diagnostics. Cold Spring Harb Perspect Med 2020;10:a037127. [PMID: 31615872 DOI: 10.1101/cshperspect.a037127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
214 Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999;96:4240-4245. [PMID: 10200246 DOI: 10.1073/pnas.96.8.4240] [Cited by in Crossref: 1395] [Cited by in F6Publishing: 1325] [Article Influence: 60.7] [Reference Citation Analysis]
215 Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-24. [PMID: 9405679 DOI: 10.1073/pnas.94.26.14719] [Cited by in Crossref: 285] [Cited by in F6Publishing: 249] [Article Influence: 11.9] [Reference Citation Analysis]
216 Liu Z, Li J, Li J, Huang J, Ke F, Qi Q, Jiang X, Zhong Z. Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice. Int J Nanomedicine 2012;7:5039-49. [PMID: 23055722 DOI: 10.2147/IJN.S34022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
217 Wang X, Jiang X. Post-translational regulation of PTEN. Oncogene 2008;27:5454-63. [PMID: 18794880 DOI: 10.1038/onc.2008.242] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
218 Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009;8:403-13. [PMID: 19177005 DOI: 10.4161/cc.8.3.7555] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
219 Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, Suri A, Gupta D, Sarkar C. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80. [PMID: 18981259 DOI: 10.1215/15228517-2008-092] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
220 Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001;20:4457-65. [PMID: 11494141 DOI: 10.1038/sj.onc.1204608] [Cited by in Crossref: 251] [Cited by in F6Publishing: 246] [Article Influence: 12.0] [Reference Citation Analysis]
221 Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99:323-334. [PMID: 10555148 DOI: 10.1016/s0092-8674(00)81663-3] [Cited by in Crossref: 730] [Cited by in F6Publishing: 376] [Article Influence: 31.7] [Reference Citation Analysis]
222 Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 2007;3:682-93. [PMID: 18046441 DOI: 10.1038/ncpneuro0661] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
223 Carnell MJ, Insall RH. Actin on disease--studying the pathobiology of cell motility using Dictyostelium discoideum. Semin Cell Dev Biol 2011;22:82-8. [PMID: 21145982 DOI: 10.1016/j.semcdb.2010.12.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
224 Gesk S, Siebert R, Wacker HH, Nürnberg N, Harder L, Lehman J, Klöppel G, Grote W, Stöckle M, Schlegelberger B. Lack of deletions of the PTEN/MMAC1 and MXI1 loci in renal cell carcinoma by interphase cytogenetics. Cancer Genet Cytogenet 2000;118:87-8. [PMID: 10766523 DOI: 10.1016/s0165-4608(99)00190-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Simons AL, Orcutt KP, Madsen JM, Scarbrough PM, Spitz DR. The Role of Akt Pathway Signaling in Glucose Metabolism and Metabolic Oxidative Stress. In: Spitz DR, Dornfeld KJ, Krishnan K, Gius D, editors. Oxidative Stress in Cancer Biology and Therapy. Totowa: Humana Press; 2012. pp. 21-46. [DOI: 10.1007/978-1-61779-397-4_2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
226 Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. Genes Dev 2000;14:505-20. [DOI: 10.1101/gad.14.5.505] [Cited by in Crossref: 95] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
227 Trapasso F, Iuliano R, Boccia A, Stella A, Visconti R, Bruni P, Baldassarre G, Santoro M, Viglietto G, Fusco A. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 2000;20:9236-46. [PMID: 11094075 DOI: 10.1128/MCB.20.24.9236-9246.2000] [Cited by in Crossref: 74] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
228 Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 2010;20:231-8. [PMID: 20456938 DOI: 10.1016/j.gde.2010.03.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
229 Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 2007;27:662-677. [PMID: 17060456 DOI: 10.1128/mcb.00537-06] [Cited by in Crossref: 112] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
230 Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said JW, Black KL, Koeffler HP. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 2010;127:2257-67. [PMID: 20162579 DOI: 10.1002/ijc.25257] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
231 Rizvi MMA, Alam MS, Ali A, Mehdi SJ, Batra S, Mandal AK. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol 2011;137:1255-62. [DOI: 10.1007/s00432-011-0994-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
232 Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 2007;101:249-57. [PMID: 17006756 DOI: 10.1007/s10549-006-9295-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
233 Bian EB, Zhao B, Huang C, Wang H, Meng XM, Wu BM, Ma TT, Zhang L, Lv XW, Li J. New advances of DNA methylation in liver fibrosis, with special emphasis on the crosstalk between microRNAs and DNA methylation machinery. Cell Signal. 2013;25:1837-1844. [PMID: 23707524 DOI: 10.1016/j.cellsig.2013.05.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
234 Hsu F, Mao Y. The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis. Biochim Biophys Acta 2015;1851:698-710. [PMID: 25264170 DOI: 10.1016/j.bbalip.2014.09.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
235 Zhang ZY. Mechanistic studies on protein tyrosine phosphatases. Prog Nucleic Acid Res Mol Biol. 2003;73:171-220. [PMID: 12882518 DOI: 10.1016/S0079-6603(03)01006-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
236 Nakabayashi H, Shimizu K. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer 2012;12:453. [PMID: 23039130 DOI: 10.1186/1471-2407-12-453] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
237 Shin KH, Choe G, Park YJ, Jang JH, Jung HW, Park JG. Establishment and characterization of nine human brain tumor cell lines. In Vitro Cell Dev Biol Anim 2001;37:625-8. [PMID: 11776963 DOI: 10.1290/1071-2690(2001)037<0625:EACONH>2.0.CO;2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
238 Chung MJ, Jung SH, Lee BJ, Kang MJ, Lee DG. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int 2004;54:10-5. [DOI: 10.1111/j.1440-1827.2004.01576.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
239 Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genetics and Cytogenetics 2005;158:1-26. [DOI: 10.1016/j.cancergencyto.2004.08.025] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
240 Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 2000;19:2687-94. [PMID: 10851068 DOI: 10.1038/sj.onc.1203587] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 2.3] [Reference Citation Analysis]
241 Ding H, Nagy A, Gutmann DH, Guha A. A review of astrocytoma models. FOC 2000;8:1-8. [DOI: 10.3171/foc.2000.8.4.2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
242 Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004;70:229-43. [PMID: 15674480 DOI: 10.1007/s11060-004-2752-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
243 Leube B, Drechsler M, Mühlmann K, Schäfer R, Schulz WA, Santourlidis S, Anastasiadis A, Ackermann R, Visakorpi T, Müller W, Royer-Pokora B. Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate 2002;50:135-44. [PMID: 11813205 DOI: 10.1002/pros.10038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
244 Kim JW, Kang KH, Burrola P, Mak TW, Lemke G. Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. Genes Dev 2008;22:3147-57. [PMID: 18997061 DOI: 10.1101/gad.1700108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
245 Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogenic PTEN functions and models in T-cell malignancies. Oncogene 2016;35:3887-96. [PMID: 26616857 DOI: 10.1038/onc.2015.462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
246 Steinbach N, Hasson D, Mathur D, Stratikopoulos EE, Sachidanandam R, Bernstein E, Parsons RE. PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription. Nucleic Acids Res 2019;47:5573-86. [PMID: 31169889 DOI: 10.1093/nar/gkz272] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
247 Cui X, Vivo ID, Slany R, Miyamoto A, Firestein R, Cleary ML. Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet 1998;18:331-7. [DOI: 10.1038/ng0498-331] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 6.9] [Reference Citation Analysis]
248 Bales SR, Chopra IJ. Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res 2011;2011:102636. [PMID: 21826256 DOI: 10.4061/2011/102636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
249 Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 2013;34:454-63. [PMID: 23125220 DOI: 10.1093/carcin/bgs346] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 13.6] [Reference Citation Analysis]
250 Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol 2011;104:155-67. [PMID: 21188471 DOI: 10.1007/s11060-010-0492-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
251 Jing P, Cao S, Xiao S, Zhang X, Ke S, Ke F, Yu X, Wang L, Wang S, Luo Y, Zhong Z. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system. Cancer Lett 2016;383:230-42. [PMID: 27721020 DOI: 10.1016/j.canlet.2016.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
252 Mendes RD, Canté-Barrett K, Pieters R, Meijerink JP. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica 2016;101:1010-7. [PMID: 27582570 DOI: 10.3324/haematol.2016.146381] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
253 Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 2012;32:190-5. [PMID: 22737980 DOI: 10.3109/10799893.2012.695798] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
254 Kawamura N, Nagai H, Bando K, Koyama M, Matsumoto S, Tajiri T, Onda M, Fujimoto J, Ueki T, Konishi N, Shiba T, Emi M. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 1999;90:413-8. [PMID: 10363579 DOI: 10.1111/j.1349-7006.1999.tb00763.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
255 Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013;2013:928562. [PMID: 24312913 DOI: 10.1155/2013/928562] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 10.3] [Reference Citation Analysis]
256 Poetsch M, Woenckhaus C, Dittberner T, Pambor M, Lorenz G, Herrmann FH. An Increased Frequency of Numerical Chromosomal Abnormalities and 1p36 Deletions in Isolated Cells from Paraffin Sections of Malignant Melanomas by Means of Interphase Cytogenetics. Cancer Genetics and Cytogenetics 1998;104:146-52. [DOI: 10.1016/s0165-4608(97)00471-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
257 Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet. 2001;125:21-26. [PMID: 11297763 DOI: 10.1016/s0165-4608(00)00353-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
258 Eng C. Constipation, polyps, or cancer? letPTEN predict your future. Am J Med Genet 2003;122A:315-22. [DOI: 10.1002/ajmg.a.20477] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
259 Adshead, Kessling, Ogden. Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. BJU Int 1998;82:503-12. [DOI: 10.1046/j.1464-410x.1998.00767.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
260 Fritz WA, Lin TM, Peterson RE. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 2008;29:1077-82. [PMID: 18359762 DOI: 10.1093/carcin/bgn069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
261 Noorolyai S, Mokhtarzadeh A, Baghbani E, Asadi M, Baghbanzadeh Kojabad A, Mogaddam MM, Baradaran B. The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer. J Cell Physiol 2019;234:5664-73. [PMID: 30488557 DOI: 10.1002/jcp.27415] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
262 Abdullah JM, Zainuddin N, Sulong S, Jaafar H, Isa MN. Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. FOC 2003;14:1-7. [DOI: 10.3171/foc.2003.14.4.6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
263 Kwak MK, Johnson DT, Zhu C, Lee SH, Ye DW, Luong R, Sun Z. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. PLoS One 2013;8:e53476. [PMID: 23308230 DOI: 10.1371/journal.pone.0053476] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
264 Watson SK, deLeeuw RJ, Horsman DE, Squire JA, Lam WL. Cytogenetically balanced translocations are associated with focal copy number alterations. Hum Genet 2007;120:795-805. [DOI: 10.1007/s00439-006-0251-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
265 Tu W, You L, Tsou A, Chen C. Pten Haplodeficiency Accelerates Liver Tumor Growth in miR-122a–Null Mice via Expansion of Periportal Hepatocyte-Like Cells. The American Journal of Pathology 2018;188:2688-702. [DOI: 10.1016/j.ajpath.2018.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
266 De Vivo I, Gertig DM, Nagase S, Hankinson SE, O'Brien R, Speizer FE, Parsons R, Hunter DJ. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet 2000;37:336-41. [PMID: 10807691 DOI: 10.1136/jmg.37.5.336] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
267 Kong B, Michalski CW, Erkan M, Friess H, Kleeff J. From tissue turnover to the cell of origin for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011;8:467-72. [DOI: 10.1038/nrgastro.2011.114] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
268 Kurose K, Araki T, Matsunaka T, Takada Y, Emi M. Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene. Am J Hum Genet 1999;64:308-10. [PMID: 9915974 DOI: 10.1086/302207] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 0.8] [Reference Citation Analysis]
269 Greener T, Zhao X, Nojima H, Eisenberg E, Greene LE. Role of Cyclin G-associated Kinase in Uncoating Clathrin-coated Vesicles from Non-neuronal Cells. Journal of Biological Chemistry 2000;275:1365-70. [DOI: 10.1074/jbc.275.2.1365] [Cited by in Crossref: 119] [Cited by in F6Publishing: 115] [Article Influence: 5.4] [Reference Citation Analysis]
270 Abkevich V, Iliev D, Timms KM, Tran T, Skolnick M, Lanchbury JS, Gutin A. Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization. J Biomed Biotechnol 2010;2010:386870. [PMID: 20706610 DOI: 10.1155/2010/386870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
271 Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, van der Kwast TH, Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208:699-707. [PMID: 16402365 DOI: 10.1002/path.1929] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
272 Bridges D, Saltiel AR. Phosphoinositides in insulin action and diabetes. Curr Top Microbiol Immunol 2012;362:61-85. [PMID: 23086413 DOI: 10.1007/978-94-007-5025-8_3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
273 DiLiberti JH. Inherited macrocephaly-hamartoma syndromes. Am J Med Genet 1998;79:284-90. [PMID: 9781909 DOI: 10.1002/(sici)1096-8628(19981002)79:4<284::aid-ajmg10>3.0.co;2-n] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
274 Giordano G, Pizzi S, Azzoni C, Bottarelli L, D'Adda T. Primary squamous cell carcinoma of the endometrium unrelated to human papilloma virus: a molecular study. Pathol Oncol Res 2013;19:495-9. [PMID: 23430758 DOI: 10.1007/s12253-013-9607-3] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
275 Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, Wu J, Li M, Li J, Song L. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat Commun 2014;5:4620. [PMID: 25099196 DOI: 10.1038/ncomms5620] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
276 Zhang L, Huang C, Guo Y, Gou X, Hinsdale M, Lloyd P, Liu L. MicroRNA-26b Modulates the NF-κB Pathway in Alveolar Macrophages by Regulating PTEN. J Immunol 2015;195:5404-14. [PMID: 26503952 DOI: 10.4049/jimmunol.1402933] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
277 B. Jenkins R, Curran W, B. Scott C, Cairncross G. Pilot Evaluation of 1p and 19q Deletions in Anaplastic Oligodendrogliomas Collected by a National Cooperative Cancer Treatment Group: . American Journal of Clinical Oncology 2001;24:506-8. [DOI: 10.1097/00000421-200110000-00018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
278 Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M, Ciuffreda L. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? Cancers (Basel) 2019;11:E435. [PMID: 30925702 DOI: 10.3390/cancers11040435] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
279 Callahan R. The Role of Tumor Suppressor Genes in Breast Cancer Progression. In: Manni A, editor. Endocrinology of Breast Cancer. Totowa: Humana Press; 1999. pp. 119-32. [DOI: 10.1007/978-1-59259-699-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
280 Gong Y, Yang H, Tian X. Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma. Exp Ther Med 2017;13:2544-50. [PMID: 28565877 DOI: 10.3892/etm.2017.4264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
281 Fragoso R, Barata JT. Kinases, tails and more: regulation of PTEN function by phosphorylation. Methods. 2015;77-78:75-81. [PMID: 25448482 DOI: 10.1016/j.ymeth.2014.10.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
282 Hwang CC, Igase M, Okuda M, Coffey M, Noguchi S, Mizuno T. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines. Biochem Biophys Res Commun 2019;517:233-7. [PMID: 31345575 DOI: 10.1016/j.bbrc.2019.07.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
283 Choi J, Jo M, Lee E, Hwang S, Choi D. Aberrant PTEN expression in response to progesterone reduces endometriotic stromal cell apoptosis. Reproduction 2017;153:11-21. [PMID: 30390418 DOI: 10.1530/REP-16-0322] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
284 Hatta Y, Yamada Y, Tomonaga M, Said JW, Miyosi I, Koeffler HP. Allelotype Analysis of Adult T-Cell Leukemia. Blood 1998;92:2113-7. [DOI: 10.1182/blood.v92.6.2113.418k25_2113_2117] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
285 Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142:164-175. [PMID: 24333502 DOI: 10.1016/j.pharmthera.2013.12.004] [Cited by in Crossref: 416] [Cited by in F6Publishing: 414] [Article Influence: 46.2] [Reference Citation Analysis]
286 Fujii GH, Morimoto AM, Berson AE, Bolen JB. Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene 1999;18:1765-9. [PMID: 10208437 DOI: 10.1038/sj.onc.1202492] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 2.5] [Reference Citation Analysis]
287 Thiery-vuillemin A, Nguyen T, Pivot X, Spano J, Dufresnne A, Soria J. Molecularly targeted agents: Their promise as cancer chemopreventive interventions. European Journal of Cancer 2005;41:2003-15. [DOI: 10.1016/j.ejca.2005.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
288 Liu Z, Zhu G, Getzenberg RH, Veltri RW. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. J Cell Biochem 2015;116:1341-9. [PMID: 25640606 DOI: 10.1002/jcb.25091] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 10.3] [Reference Citation Analysis]
289 Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98:10031-10033. [PMID: 11526226 DOI: 10.1073/pnas.191379498] [Cited by in Crossref: 96] [Cited by in F6Publishing: 81] [Article Influence: 4.6] [Reference Citation Analysis]
290 Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opinion on Investigational Drugs 2009;18:1061-83. [DOI: 10.1517/13543780903052764] [Cited by in Crossref: 316] [Cited by in F6Publishing: 304] [Article Influence: 24.3] [Reference Citation Analysis]
291 Park JK, Jung HY, Park SH, Kang SY, Yi MR, Um HD, Hong SH. Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys. 2008;70:1552-1560. [PMID: 18374229 DOI: 10.1016/j.ijrobp.2007.11.069] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
292 Pomerantz JH, Blau HM. Tumor suppressors: enhancers or suppressors of regeneration? Development 2013;140:2502-12. [PMID: 23715544 DOI: 10.1242/dev.084210] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
293 Li X, Yang Y, Zhang H, Yue W, Zhang T, Lu B, Li J, Liu Z, Wang Q, Gao Y, Hu A, Zhang H, Shi H, Hu F, Li B. High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer. Cell Biochem Biophys 2015;73:631-7. [DOI: 10.1007/s12013-015-0671-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
294 Merg A, Howe JR. Genetic conditions associated with intestinal juvenile polyps. Am J Med Genet 2004;129C:44-55. [DOI: 10.1002/ajmg.c.30020] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
295 Hlobilková A, Knillová J, Bártek J, Lukás J, Kolár Z. The mechanism of action of the tumour suppressor gene PTEN. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003;147:19-25. [PMID: 15034601 DOI: 10.5507/bp.2003.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
296 Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. PTEN enters the nucleus by diffusion. J Cell Biochem 2005;96:221-34. [DOI: 10.1002/jcb.20525] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 4.8] [Reference Citation Analysis]
297 Biondani G, Peyron JF. Metformin, an Anti-diabetic Drug to Target Leukemia. Front Endocrinol (Lausanne). 2018;9:446. [PMID: 30147674 DOI: 10.3389/fendo.2018.00446] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
298 Hu L, Jiang GY, Wang YP, Hu ZB, Zhou BY, Zhang L, Song NN, Huang Y, Chai GD, Chen JY, Lang B, Xu L, Liu JL, Li Y, Wang QX, Ding YQ. The role of PTEN in primary sensory neurons in processing itch and thermal information in mice. Cell Rep 2022;39:110724. [PMID: 35443189 DOI: 10.1016/j.celrep.2022.110724] [Reference Citation Analysis]
299 Lieberman-Cribbin W, Tuminello S, Gillezeau C, van Gerwen M, Brody R, Mulholland DJ, Horton L, Sisco M, Prophete C, Zelikoff J, Lee HW, Park SH, Chen LC, Cohen MD, Taioli E. Complementary biobank of rodent tissue samples to study the effect of World Trade Center exposure on cancer development. J Transl Med 2019;17:342. [PMID: 31601237 DOI: 10.1186/s12967-019-2089-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
300 Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, Tombolini V. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305. [PMID: 21108789 DOI: 10.1186/1476-4598-9-305] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
301 Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet 2013;163C:114-21. [PMID: 23613428 DOI: 10.1002/ajmg.c.31364] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 9.7] [Reference Citation Analysis]
302 Chang H, Cai Z, Roberts TM. The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules 2019;9:E713. [PMID: 31703360 DOI: 10.3390/biom9110713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
303 Trojan J, Plotz G, Brieger A, Raedle J, Meltzer SJ, Wolter M, Zeuzem S. Activation of a cryptic splice site of PTEN and loss of heterozygosity in benign skin lesions in Cowden disease. J Invest Dermatol 2001;117:1650-3. [PMID: 11886535 DOI: 10.1046/j.0022-202x.2001.01954.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
304 Walker CJ, Goodfellow PJ. Traditional Approaches to Molecular Genetic Analysis. In: Hedrick Ellenson L, editor. Molecular Genetics of Endometrial Carcinoma. Cham: Springer International Publishing; 2017. pp. 99-118. [DOI: 10.1007/978-3-319-43139-0_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
305 Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M, Rosser CJ. Combination of PTEN Gene Therapy and Radiation Inhibits the Growth of Human Prostate Cancer Xenografts. Human Gene Therapy 2006;17:975-84. [DOI: 10.1089/hum.2006.17.975] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
306 Johansson Swartling F. Identifying candidate genes involved in brain tumor formation. Ups J Med Sci 2008;113:1-38. [PMID: 18521796 DOI: 10.3109/2000-1967-215] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
307 Terracciano L, Richter J, Tornillo L, Beffa L, Diener P, Maurer R, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol 1999;189:230-5. [DOI: 10.1002/(sici)1096-9896(199910)189:2<230::aid-path407>3.0.co;2-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
308 Hatta Y, Yamada Y, Tomonaga M, Said JW, Miyosi I, Koeffler HP. Allelotype Analysis of Adult T-Cell Leukemia. Blood 1998;92:2113-7. [DOI: 10.1182/blood.v92.6.2113] [Cited by in Crossref: 18] [Article Influence: 0.8] [Reference Citation Analysis]
309 Sakurada A, Suzuki A, Sato M, Yamakawa H, Orikasa K, Uyeno S, Ono T, Ohuchi N, Fujimura S, Horii A. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 1997;88:1025-8. [PMID: 9439675 DOI: 10.1111/j.1349-7006.1997.tb00324.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 3.0] [Reference Citation Analysis]
310 Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, Mccubrey JA. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707. [DOI: 10.1038/leu.2008.26] [Cited by in Crossref: 251] [Cited by in F6Publishing: 246] [Article Influence: 17.9] [Reference Citation Analysis]
311 Rosasco MG, Gordon SE, Bajjalieh SM. Characterization of the Functional Domains of a Mammalian Voltage-Sensitive Phosphatase. Biophys J 2015;109:2480-91. [PMID: 26682807 DOI: 10.1016/j.bpj.2015.11.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
312 Sarmay G. Phosphatidylinositol 3-kinase, Phosphoinositides and Apoptosis. In: Quinn PJ, Kagan VE, editors. Phospholipid Metabolism in Apoptosis. Boston: Kluwer Academic Publishers; 2004. pp. 309-33. [DOI: 10.1007/0-306-47931-1_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
313 Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am J Pathol 2013;182:975-91. [PMID: 23313138 DOI: 10.1016/j.ajpath.2012.11.025] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 7.4] [Reference Citation Analysis]
314 Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253:1-6. [PMID: 10579905 DOI: 10.1006/excr.1999.4667] [Cited by in Crossref: 192] [Cited by in F6Publishing: 186] [Article Influence: 8.3] [Reference Citation Analysis]
315 Fackenthal JD, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, Olopade OI. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001;38:159-64. [PMID: 11238682 DOI: 10.1136/jmg.38.3.159] [Cited by in Crossref: 122] [Cited by in F6Publishing: 90] [Article Influence: 5.8] [Reference Citation Analysis]
316 Kleijer KT, Schmeisser MJ, Krueger DD, Boeckers TM, Scheiffele P, Bourgeron T, Brose N, Burbach JP. Neurobiology of autism gene products: towards pathogenesis and drug targets. Psychopharmacology (Berl) 2014;231:1037-62. [PMID: 24419271 DOI: 10.1007/s00213-013-3403-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
317 Heinrich F, Chakravarthy S, Nanda H, Papa A, Pandolfi PP, Ross AH, Harishchandra RK, Gericke A, Lösche M. The PTEN Tumor Suppressor Forms Homodimers in Solution. Structure 2015;23:1952-7. [PMID: 26299948 DOI: 10.1016/j.str.2015.07.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
318 Minobe K, Bando K, Fukino K, Soma S, Kasumi F, Sakamoto G, Furukawa K, Higuchi K, Onda M, Nakamura Y, Emi M. Somatic mutation of the PTEN/MMAC1 gene in breast cancers with microsatellite instability. Cancer Letters 1999;144:9-16. [DOI: 10.1016/s0304-3835(99)00181-0] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
319 Srikantan V, Srivastava S. Molecular Dissection of the Prostate Cancer Genome. In: Hofmann R, Heidenreich A, Moul JW, editors. Prostate Cancer. Berlin: Springer Berlin Heidelberg; 2003. pp. 25-40. [DOI: 10.1007/978-3-642-56321-8_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
320 Alimonti A. PTEN breast cancer susceptibility: a matter of dose. Ecancermedicalscience 2010;4:192. [PMID: 22276040 DOI: 10.3332/ecancer.2010.192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
321 Moretti L, Yang ES, Kim KW, Lu B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resistance Updates 2007;10:135-43. [DOI: 10.1016/j.drup.2007.05.001] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 5.9] [Reference Citation Analysis]
322 Newton HB. Overview of the Molecular Genetics and Molecular Chemotherapy of GBM. In: Ray SK, editor. Glioblastoma. New York: Springer; 2010. pp. 1-42. [DOI: 10.1007/978-1-4419-0410-2_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
323 Wu YH, Huang YF, Chen CC, Chou CY. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression. Cell Death Dis 2019;10:322. [PMID: 30975980 DOI: 10.1038/s41419-019-1555-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
324 Chernova O, Cowell JK. Molecular Definition of Chromosome Translocations Involving 10q24 and 19q13 in Human Malignant Glioma Cells. Cancer Genetics and Cytogenetics 1998;105:60-8. [DOI: 10.1016/s0165-4608(97)00479-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
325 Nothnick WB, Peterson R, Minchella P, Falcone T, Graham A, Findley A. The Relationship and Expression of miR-451a, miR-25-3p and PTEN in Early Peritoneal Endometriotic Lesions and Their Modulation In Vitro. Int J Mol Sci 2022;23:5862. [PMID: 35682544 DOI: 10.3390/ijms23115862] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res 2014;74:3180-94. [PMID: 24662921 DOI: 10.1158/0008-5472.CAN-13-3415] [Cited by in Crossref: 73] [Cited by in F6Publishing: 49] [Article Influence: 9.1] [Reference Citation Analysis]
327 Lee SH, Lee YP, Kim SY, Jeong MS, Lee MJ, Kang HW, Jeong HJ, Kim DW, Sohn EJ, Jang SH, Kim YH, Kwon HJ, Cho SW, Park J, Eum WS, Choi SY. Inhibition of LPS-induced cyclooxygenase 2 and nitric oxide production by transduced PEP-1-PTEN fusion protein in Raw 264.7 macrophage cells. Exp Mol Med 2008;40:629-38. [PMID: 19116448 DOI: 10.3858/emm.2008.40.6.629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
328 Dasgupta P, Kulkarni P, Majid S, Shahryari V, Hashimoto Y, Bhat NS, Shiina M, Deng G, Saini S, Tabatabai ZL, Yamamura S, Tanaka Y, Dahiya R. MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma. Mol Cancer Ther 2018;17:1061-9. [PMID: 29440295 DOI: 10.1158/1535-7163.MCT-17-0925] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
329 Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007;102:1368-74. [DOI: 10.1002/jcb.21593] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
330 Fedorko AM, Kim TH, Broaddus R, Schmandt R, Chandramouli GVR, Kim HI, Jeong JW, Risinger JI. An immune competent orthotopic model of endometrial cancer with metastasis. Heliyon 2020;6:e04075. [PMID: 32490257 DOI: 10.1016/j.heliyon.2020.e04075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
331 Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y, Rong H, Wang W, Zhang D, Zhang Z, Tu S, Zhu X, Zhang Q. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res 2019;11:4023-40. [PMID: 31190980 DOI: 10.2147/CMAR.S198886] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
332 Jia H, Sun W, Li X, Xu W. Melatonin promotes apoptosis of thyroid cancer cells via regulating the signaling of microRNA-21 (miR-21) and microRNA-30e (miR-30e). Bioengineered 2022;13:9588-601. [PMID: 35412442 DOI: 10.1080/21655979.2022.2054206] [Reference Citation Analysis]
333 Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2011;32:703-740. [PMID: 22054881 DOI: 10.1016/j.ccm.2011.08.003] [Cited by in Crossref: 126] [Cited by in F6Publishing: 112] [Article Influence: 11.5] [Reference Citation Analysis]
334 Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000;20:1626-38. [PMID: 10669740 DOI: 10.1128/MCB.20.5.1626-1638.2000] [Cited by in Crossref: 487] [Cited by in F6Publishing: 142] [Article Influence: 22.1] [Reference Citation Analysis]
335 Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2011;51:37-49. [PMID: 21035501 DOI: 10.1016/j.advenzreg.2010.09.012] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
336 Su T, Chang J, Perng L, Chang C, Wei H, Wang NM, Tsai C. Mutation Analysis of the Putative Tumor Suppressor Gene PTEN/MMAC1 in Cervical Cancer. Gynecologic Oncology 2000;76:193-9. [DOI: 10.1006/gyno.1999.5659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
337 Jezek J, Wang K, Yan R, Di Cristofano A, Cooper KF, Strich R. Synergistic repression of thyroid hyperplasia by cyclin C and Pten. J Cell Sci 2019;132:jcs230029. [PMID: 31331961 DOI: 10.1242/jcs.230029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
338 Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet 2009;5:e1000542. [PMID: 19578399 DOI: 10.1371/journal.pgen.1000542] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
339 Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 2020;20:25-39. [PMID: 31570880 DOI: 10.1038/s41577-019-0218-4] [Cited by in Crossref: 217] [Cited by in F6Publishing: 216] [Article Influence: 72.3] [Reference Citation Analysis]
340 Tachibana I, Smith JS, Sato K, Hosek SM, Kimmel DW, Jenkins RB. Investigation of germline PTEN, p53, p16INK4A/p14ARF, and CDK4 alterations in familial glioma. Am J Med Genet 2000;92:136-41. [DOI: 10.1002/(sici)1096-8628(20000515)92:2<136::aid-ajmg11>3.0.co;2-s] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
341 Kriplani N, Hermida MA, Brown ER, Leslie NR. Class I PI 3-kinases: Function and evolution. Advances in Biological Regulation 2015;59:53-64. [DOI: 10.1016/j.jbior.2015.05.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
342 Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95:15406-15411. [PMID: 9860981 DOI: 10.1073/pnas.95.26.15406] [Cited by in Crossref: 323] [Cited by in F6Publishing: 306] [Article Influence: 14.0] [Reference Citation Analysis]
343 Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T, Dai F. PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 2010;136:1303-11. [DOI: 10.1007/s00432-010-0781-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
344 Houlston R, Bevan S, Williams A, Young J, Dunlop M, Rozen P, Eng C, Markie D, Woodford-Richens K, Rodriguez-Bigas MA, Leggett B, Neale K, Phillips R, Sheridan E, Hodgson S, Iwama T, Eccles D, Bodmer W, Tomlinson I. Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. Hum Mol Genet 1998;7:1907-12. [PMID: 9811934 DOI: 10.1093/hmg/7.12.1907] [Cited by in Crossref: 93] [Cited by in F6Publishing: 73] [Article Influence: 3.9] [Reference Citation Analysis]
345 Sutphen R, Diamond TM, Minton SE, Peacocke M, Tsou HC, Root AW. Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. Am J Med Genet 1999;82:290-3. [PMID: 10051160 DOI: 10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
346 Narla G, Sangodkar J, Ryder CB. The impact of phosphatases on proliferative and survival signaling in cancer. Cell Mol Life Sci 2018;75:2695-718. [PMID: 29725697 DOI: 10.1007/s00018-018-2826-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
347 Zhuang W, Qin Z, Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 2009;41:341-51. [PMID: 19430698 DOI: 10.1093/abbs/gmp028] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
348 Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000;19:3146-55. [PMID: 10918569 DOI: 10.1038/sj.onc.1203633] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 4.7] [Reference Citation Analysis]
349 Yang H, Wang L, Shigley C, Yang W. Protein tyrosine phosphatases in skeletal development and diseases. Bone Res 2022;10. [DOI: 10.1038/s41413-021-00181-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Liang H, Chen X, Yin Q, Ruan D, Zhao X, Zhang C, McNutt MA, Yin Y. PTENβ is an alternatively translated isoform of PTEN that regulates rDNA transcription. Nat Commun 2017;8:14771. [PMID: 28332494 DOI: 10.1038/ncomms14771] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 11.6] [Reference Citation Analysis]
351 Qin YM, Han Y, Zhang CX, Chang TM. Correlation of PTEN expression with microvessel density and pathological parameters in esophageal carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(29): 3023-3027 [DOI: 10.11569/wcjd.v17.i29.3023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
352 Baldinu P, Cossu A, Manca A, Satta MP, Pisano M, Casula M, Dessole S, Pintus A, Tanda F, Palmieri G. Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer 2002;94:3157-68. [DOI: 10.1002/cncr.10606] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
353 Mezey G, Treszl A, Schally AV, Block NL, Vízkeleti L, Juhász A, Klekner Á, Nagy J, Balázs M, Halmos G, Bognár L. Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. J Cancer Res Clin Oncol 2014;140:1641-9. [DOI: 10.1007/s00432-014-1716-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
354 Ge H, Cao YY, Chen LQ, Wang YM, Chen ZF, Wen DG, Zhang XF, Guo W, Wang N, Li Y. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. Dis Esophagus. 2008;21:409-415. [PMID: 19125794 DOI: 10.1111/j.1442-2050.2007.00786.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
355 Van Meir EG, Bellail A, Phuphanich S. Emerging molecular therapies for brain tumors. Seminars in Oncology 2004;31:38-46. [DOI: 10.1053/j.seminoncol.2004.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
356 Li PE, Nelson PS. Prostate cancer genomics. Curr Urol Rep 2001;2:70-8. [PMID: 12084298 DOI: 10.1007/s11934-001-0028-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
357 El-Mansi MT, Williams AR. Evaluation of PTEN expression in cervical adenocarcinoma by tissue microarray. Int J Gynecol Cancer 2006;16:1254-60. [PMID: 16803514 DOI: 10.1111/j.1525-1438.2006.00569.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
358 Zha X, Hu Z, He S, Wang F, Shen H, Zhang H. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 2011;313:211-7. [PMID: 22055460 DOI: 10.1016/j.canlet.2011.09.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
359 Mentel M, Laketa V, Subramanian D, Gillandt H, Schultz C. Photoaktivierbares und zellmembranpermeables Phosphatidylinositol-3,4,5-trisphosphat. Angew Chem 2011;123:3895-8. [DOI: 10.1002/ange.201007796] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
360 Myers MP, Tonks NK. PTEN: sometimes taking it off can be better than putting it on. Am J Hum Genet 1997;61:1234-8. [PMID: 9399917 DOI: 10.1086/301659] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 2.3] [Reference Citation Analysis]
361 Zhang H, Wang Y, Xie JF, Liang X, Liu D, Yang P, Hsu H, Ray RB, Mountz JD. Regulation of tumor necrosis factor ?-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis & Rheumatism 2001;44:1555-67. [DOI: 10.1002/1529-0131(200107)44:7<1555::aid-art279>3.0.co;2-m] [Cited by in Crossref: 83] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
362 Fan C, Zhao C, Wang F, Li S, Wang J. Significance of PTEN Mutation in Cellular Process, Prognosis, and Drug Selection in Clear Cell Renal Cell Carcinoma. Front Oncol 2019;9:357. [PMID: 31139560 DOI: 10.3389/fonc.2019.00357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
363 Staal FJ, van der Luijt RB, Baert MR, van Drunen J, van Bakel H, Peters E, de Valk I, van Amstel HK, Taphoorn MJ, Jansen GH, van Veelen CW, Burgering B, Staal GE. A novel germline mutation of PTEN associated with brain tumours of multiple lineages. Br J Cancer 2002;86:1586-91. [PMID: 12085208 DOI: 10.1038/sj.bjc.6600206] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
364 Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J, Tsao MS, Shannon P, Bolon B, Ivy GO, Mak TW. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001;29:396-403. [PMID: 11726926 DOI: 10.1038/ng782] [Cited by in Crossref: 339] [Cited by in F6Publishing: 329] [Article Influence: 16.1] [Reference Citation Analysis]
365 Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 2009;4:43. [PMID: 19828040 DOI: 10.1186/1748-717x-4-43] [Cited by in Crossref: 122] [Cited by in F6Publishing: 73] [Article Influence: 9.4] [Reference Citation Analysis]
366 Ng HK, Lam PY. The molecular genetics of central nervous system tumors. Pathology 1998;30:196-202. [PMID: 9643506 DOI: 10.1080/00313029800169236] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
367 Nielsen-Preiss SM, Silva SR, Gillette JM. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells. J Cell Biochem. 2003;90:964-975. [PMID: 14624456 DOI: 10.1002/jcb.10709] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
368 Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer 2008;15:657-64. [PMID: 18524948 DOI: 10.1677/ERC-08-0019] [Cited by in Crossref: 115] [Cited by in F6Publishing: 76] [Article Influence: 8.2] [Reference Citation Analysis]
369 Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer 2017;17:638. [PMID: 28886696 DOI: 10.1186/s12885-017-3639-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
370 Forscher C, Mita M, Figlin R. Targeted therapy for sarcomas. Biologics 2014;8:91-105. [PMID: 24669185 DOI: 10.2147/BTT.S26555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
371 Hausott B, Glueckert R, Schrott-fischer A, Klimaschewski L. Signal Transduction Regulators in Axonal Regeneration. Cells 2022;11:1537. [DOI: 10.3390/cells11091537] [Reference Citation Analysis]
372 Kwon CH, Zhu X, Zhang J, Knoop LL, Tharp R, Smeyne RJ, Eberhart CG, Burger PC, Baker SJ. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001;29:404-11. [PMID: 11726927 DOI: 10.1038/ng781] [Cited by in Crossref: 314] [Cited by in F6Publishing: 313] [Article Influence: 15.0] [Reference Citation Analysis]
373 Capodanno A, Camerini A, Orlandini C, Baldini E, Resta ML, Bevilacqua G, Collecchi P. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol. 2009;40:1408-1417. [PMID: 19428048 DOI: 10.1016/j.humpath.2009.02.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
374 Li M, Peng J, Shi Y, Sun P. miR-92a promotes progesterone resistance in endometriosis through PTEN/AKT pathway. Life Sciences 2020;242:117190. [DOI: 10.1016/j.lfs.2019.117190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
375 Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Kang J, Qin CY. Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med 2013;5:57-64. [PMID: 23251242 DOI: 10.3892/etm.2012.749] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
376 Grønbæk K, Zeuthen J, Guldberg P, Ralfkiær E, Hou-jensen K. Alterations of the MMAC1/PTEN Gene in Lymphoid Malignancies. Blood 1998;91:4388-90. [DOI: 10.1182/blood.v91.11.4388] [Cited by in Crossref: 43] [Article Influence: 1.8] [Reference Citation Analysis]
377 Santra M, Zheng X, Roberts C, Santra S, Lu M, Panda S, Jiang F, Chopp M. Single doublecortin gene therapy significantly reduces glioma tumor volume. J Neurosci Res 2010;88:304-14. [PMID: 19681167 DOI: 10.1002/jnr.22207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
378 Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J. PTEN: A crucial mediator of mitochondria-dependent apoptosis. Apoptosis 2006;11:197-207. [DOI: 10.1007/s10495-006-3714-5] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 5.6] [Reference Citation Analysis]
379 Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh M, Sakon M, Nishisho I, Monden M. PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res. 2000;91:287-292. [PMID: 10760687 DOI: 10.1111/j.1349-7006.2000.tb00943.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.3] [Reference Citation Analysis]
380 Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006;24:288-95. [PMID: 16344319 DOI: 10.1200/JCO.2005.02.2418] [Cited by in Crossref: 79] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
381 Wu ZX, Song TB, Li DM, Zhang XT, Wu XL. Overexpression of PTEN suppresses growth and induces apoptosis by inhibiting the expression of survivin in bladder cancer cells. Tumour Biol. 2007;28:9-15. [PMID: 17108713 DOI: 10.1159/000097041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
382 Mccabe MG, Ichimura K, Pearson DM, Liu L, Clifford SC, Ellison DW, Collins VP. Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromosom Cancer 2009;48:121-31. [DOI: 10.1002/gcc.20625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
383 Smith A, Ashworth A. Cancer predisposition: where's the phosphate? Curr Biol 1998;8:R241-3. [PMID: 9545192 DOI: 10.1016/s0960-9822(98)70150-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
384 Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, Aaltonen LA, Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161:439-447. [PMID: 12163369 DOI: 10.1016/s0002-9440(10)64200-9] [Cited by in Crossref: 131] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
385 Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378. [PMID: 9593664 DOI: 10.1074/jbc.273.22.13375] [Cited by in Crossref: 2085] [Cited by in F6Publishing: 2030] [Article Influence: 86.9] [Reference Citation Analysis]
386 Li J, Di C, Mattox AK, Wu L, Adamson DC. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med 2010;3:111-27. [PMID: 23226047 DOI: 10.2147/PGPM.S6852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
387 Abounader R, Reznik T, Colantuoni C, Martinez-Murillo F, Rosen EM, Laterra J. Regulation of c-Met-dependent gene expression by PTEN. Oncogene. 2004;23:9173-9182. [PMID: 15516982 DOI: 10.1038/sj.onc.1208146] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
388 Choi SW, Lee Y, Shin K, Koo H, Kim D, Sa JK, Cho HJ, Shin HM, Lee SJ, Kim H, Chung S, Shin J, Lee C, Nam DH. Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell Death Dis 2021;12:374. [PMID: 33828082 DOI: 10.1038/s41419-021-03657-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
389 Shin SY, Choi BH, Ko J, Kim SH, Kim YS, Lee YH. Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca2+/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cellular Signalling 2006;18:1876-86. [DOI: 10.1016/j.cellsig.2006.02.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
390 Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125:4687-4692. [PMID: 23223894 DOI: 10.1242/jcs.093765] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
391 Park CE, Yun H, Lee EB, Min BI, Bae H, Choe W, Kang I, Kim SS, Ha J. The antioxidant effects of genistein are associated with AMP-activated protein kinase activation and PTEN induction in prostate cancer cells. J Med Food 2010;13:815-20. [PMID: 20673057 DOI: 10.1089/jmf.2009.1359] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
392 Li B, Zhang J, Su Y, Hou Y, Wang Z, Zhao L, Sun S, Fu H. Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism. Mol Med Rep 2019;20:3793-801. [PMID: 31485626 DOI: 10.3892/mmr.2019.10617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
393 Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, Shi X. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res 2018;37:324. [PMID: 30591064 DOI: 10.1186/s13046-018-0965-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 111] [Article Influence: 24.3] [Reference Citation Analysis]
394 Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67. [PMID: 11438483 DOI: 10.1016/S0002-9440(10)61702-6] [Cited by in Crossref: 111] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
395 Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL; Children's Oncology Group. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006;105:418-24. [PMID: 17328268 DOI: 10.3171/ped.2006.105.5.418] [Cited by in Crossref: 25] [Cited by in F6Publishing: 70] [Article Influence: 1.7] [Reference Citation Analysis]
396 Ding X, Li F, McKnight J, Schmidt C, Strooisma K, Shimizu H, Faber K, Ware JA, Dean B. A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. J Pharm Biomed Anal 2014;100:150-6. [PMID: 25165011 DOI: 10.1016/j.jpba.2014.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
397 Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008;27:5443-53. [PMID: 18794879 DOI: 10.1038/onc.2008.241] [Cited by in Crossref: 241] [Cited by in F6Publishing: 234] [Article Influence: 17.2] [Reference Citation Analysis]
398 Yang L, Wang Y, Chen P, Hu J, Xiong Y, Feng D, Liu H, Zhang H, Yang H, He J. Na(+)/H(+) Exchanger Regulatory Factor 1 (NHERF1) Is Required for the Estradiol-Dependent Increase of Phosphatase and Tensin Homolog (PTEN) Protein Expression. Endocrinology 2011;152:4537-49. [DOI: 10.1210/en.2011-1207] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
399 Scully C, Field J, Tanzawa H. Oncogenes and Tumor Suppressor Genes in Oral or Head and Neck Squamous Cell Carcinoma. Head and Neck Cancer. Elsevier; 2003. pp. 117-35. [DOI: 10.1016/b978-012239990-9/50010-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
400 Tsujiuchi T, Sasaki Y, Tsutsumi M, Konishi Y. Absence of PTEN/MMAC1 gene mutations in lung adenocarcinomas induced by N -nitrosobis(2-hydroxypropyl)amine in rats. Cancer Letters 2001;162:207-11. [DOI: 10.1016/s0304-3835(00)00655-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
401 Elo JP, Visakorpi T. Molecular genetics of prostate cancer. Annals of Medicine 2009;33:130-41. [DOI: 10.3109/07853890109002068] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
402 Merlo A, Bettler B. Glioblastomas on the Move. Science Signaling 2004;2004:pe18-pe18. [DOI: 10.1126/stke.2292004pe18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
403 Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J, Tan SS. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signal. 2012;5:ra70. [PMID: 23012657 DOI: 10.1126/scisignal.2003084] [Cited by in Crossref: 188] [Cited by in F6Publishing: 185] [Article Influence: 18.8] [Reference Citation Analysis]
404 Haynie DT, Xue B. Superdomains in the protein structure hierarchy: The case of PTP-C2. Protein Sci 2015;24:874-82. [PMID: 25694109 DOI: 10.1002/pro.2664] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
405 Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, Huang B. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 2007;109:1676-88. [PMID: 17330857 DOI: 10.1002/cncr.22585] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
406 Huang X, Begley M, Morgenstern KA, Gu Y, Rose P, Zhao H, Zhu X. Crystal structure of an inactive Akt2 kinase domain. Structure 2003;11:21-30. [PMID: 12517337 DOI: 10.1016/s0969-2126(02)00937-1] [Cited by in Crossref: 92] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
407 Grapsa D, Frangou-plemenou M, Kondi-pafiti A, Stergiou E, Nicolopoulou-stamati P, Patsouris E, Chelidonis G, Athanassiadou P. “Immunocytochemical expression of P53, PTEN, FAS (CD95), P16INK4A and HPV L1 major capsid proteins in ThinPrep cervical samples with squamous intraepithelial lesions”: Apoptosis Markers in Cervical Lesions. Diagn Cytopathol 2014;42:465-75. [DOI: 10.1002/dc.23003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
408 Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999;154:1329-34. [PMID: 10329585 DOI: 10.1016/S0002-9440(10)65386-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
409 Takeshima H, Sawamura Y, Gilbert MR, Meir EGV. Application of advances in molecular biology to the treatment of brain tumors. Curr Oncol Rep 2000;2:425-33. [DOI: 10.1007/s11912-000-0062-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
410 Hamilton JA, Stewart LM, Ajayi L, Gray IC, Gray NE, Roberts KG, Watson GJ, Kaisary AV, Snary D. The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers. Br J Cancer 2000;82:1671-6. [PMID: 10817502 DOI: 10.1054/bjoc.2000.1211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
411 O'Brien B, Jossart GH, Ito Y, Greulich-Bode KM, Weier JF, Munne S, Clark OH, Weier HU. 'Chromosomal Rainbows' Detect Oncogenic Rearrangements of Signaling Molecules in Thyroid Tumors. Open Cell Signal J 2010;2:13-22. [PMID: 22328910 DOI: 10.2172/1011038] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
412 Gimm O, Gössling A, Marsh DJ, Dahia PL, Mulligan LM, von Deimling A, Eng C. Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours. Br J Cancer 1999;80:383-6. [PMID: 10408842 DOI: 10.1038/sj.bjc.6690367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
413 Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128:141-156. [PMID: 17218261 DOI: 10.1016/j.cell.2006.11.040] [Cited by in Crossref: 495] [Cited by in F6Publishing: 493] [Article Influence: 33.0] [Reference Citation Analysis]
414 Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther. 2001;90:105-156. [PMID: 11578655 DOI: 10.1016/s0163-7258(01)00132-2] [Cited by in Crossref: 204] [Cited by in F6Publishing: 74] [Article Influence: 9.7] [Reference Citation Analysis]
415 Cool M, Depault F, Jolicoeur P. Fine allelotyping ofErbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci. Genes Chromosom Cancer 2006;45:191-202. [DOI: 10.1002/gcc.20276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
416 Yang L, Kuang LG, Zheng HC, Li JY, Wu DY, Zhang SM, Xin Y, Chen Y, Yang S. PTEN encoding product: A marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol 2003; 9(1): 35-39 [PMID: 12508347 DOI: 10.3748/wjg.v9.i1.35] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
417 Molina JR, Hayashi Y, Stephens C, Georgescu MM. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 2010;12:453-63. [PMID: 20563248 DOI: 10.1593/neo.10126] [Cited by in Crossref: 137] [Cited by in F6Publishing: 132] [Article Influence: 11.4] [Reference Citation Analysis]
418 Yamakawa H, Nagase S, Yuki M, Shiwaku HO, Furukawa T, Yoshinaga K, Soeda E, Hoshi M, Hayashi Y, Sato S, Yajima A, Horii A. Identification of a 100-kb region of common allelic loss on chromosome bands 10q25–q26 in human endometrial cancer. Genes Chromosom Cancer 1998;23:74-7. [DOI: 10.1002/(sici)1098-2264(199809)23:1<74::aid-gcc12>3.0.co;2-e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
419 Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet. 1997;17:32-39. [PMID: 9288095 DOI: 10.1038/ng0997-32] [Cited by in Crossref: 301] [Cited by in F6Publishing: 281] [Article Influence: 12.0] [Reference Citation Analysis]
420 Deb TB, Barndt RJ, Zuo AH, Sengupta S, Coticchia CM, Johnson MD. PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression. Cell Cycle 2014;13:961-73. [PMID: 24552815 DOI: 10.4161/cc.27837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
421 Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, Hashimoto Y, Shiina M, Kulkarni P, Dasgupta P, Imai-Sumida M, Tabatabai ZL, Greene K, Deng G, Dahiya R, Majid S. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget 2016;7:68371-84. [PMID: 27634912 DOI: 10.18632/oncotarget.12031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
422 Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. European Journal of Cancer 2013;49:1297-304. [DOI: 10.1016/j.ejca.2012.11.019] [Cited by in Crossref: 238] [Cited by in F6Publishing: 206] [Article Influence: 26.4] [Reference Citation Analysis]
423 Inoue T, Kobayashi T, Terada N, Shimizu Y, Kamoto T, Ogawa O, Nakamura E. Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology & Metabolism 2014;2:689-704. [DOI: 10.1586/17446651.2.5.689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
424 Li L, Liu F, Salmonsen RA, Turner TK, Litofsky NS, Di Cristofano A, Pandolfi PP, Jones SN, Recht LD, Ross AH. PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci 2002;20:21-9. [PMID: 12056837 DOI: 10.1006/mcne.2002.1115] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 4.7] [Reference Citation Analysis]
425 Wang Z, Li N, Wang B, Lin J. Nonalcoholic fatty liver disease progression in rats is accelerated by splenic regulation of liver PTEN/AKT. Saudi J Gastroenterol 2015;21:232-8. [PMID: 26228367 DOI: 10.4103/1319-3767.161641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
426 Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, Mcdonnell TJ, Kuban DA, Meyn RE. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 2004;11:273-9. [DOI: 10.1038/sj.cgt.7700673] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
427 Kozicky LK, Sly LM. Phosphatase regulation of macrophage activation. Seminars in Immunology 2015;27:276-85. [DOI: 10.1016/j.smim.2015.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
428 Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, Kelsey KT. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005;36:768-76. [PMID: 16084946 DOI: 10.1016/j.humpath.2005.05.006] [Cited by in Crossref: 173] [Cited by in F6Publishing: 174] [Article Influence: 10.2] [Reference Citation Analysis]
429 Siepmann M, Kumar S, Mayer G, Walter J. Casein kinase 2 dependent phosphorylation of neprilysin regulates receptor tyrosine kinase signaling to Akt. PLoS One 2010;5:e13134. [PMID: 20957047 DOI: 10.1371/journal.pone.0013134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
430 Reiser J, Pixley FJ, Hug A, Kriz W, Smoyer WE, Stanley ER, Mundel P. Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases. Kidney International 2000;57:2035-42. [DOI: 10.1046/j.1523-1755.2000.00070.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 2.2] [Reference Citation Analysis]
431 Ma DZ, Xu Z, Liang YL, Su JM, Li ZX, Zhang W, Wang LY, Zha XL. Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol 2005; 11(29): 4472-4477 [PMID: 16052674 DOI: 10.3748/wjg.v11.i29.4472] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
432 Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003;22:2135-2142. [PMID: 12687015 DOI: 10.1038/sj.onc.1206232] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 5.3] [Reference Citation Analysis]
433 Xia S, Lu Y, Wang J, He C, Hong S, Serhan CN, Kang JX. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A 2006;103:12499-504. [PMID: 16888035 DOI: 10.1073/pnas.0605394103] [Cited by in Crossref: 103] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
434 Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It's all about diversity. Semin Cancer Biol 2019;59:66-79. [PMID: 30738865 DOI: 10.1016/j.semcancer.2019.02.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 17.7] [Reference Citation Analysis]
435 Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T, Waldman T. Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Mol Cell Biol. 2011;31:2756-2771. [PMID: 21536651 DOI: 10.1128/mcb.01323-10] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
436 Tong, Ng H, Pang, Hui, Ko, Lee. Molecular genetic analysis of non-astrocytic gliomas: Molecular genetic analysis of non-astrocytic gliomas. Histopathology 1999;34:331-41. [DOI: 10.1046/j.1365-2559.1999.00603.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
437 Leslie NR, Gray A, Pass I, Orchiston EA, Downes CP. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochem J. 2000;346 Pt 3:827-833. [PMID: 10698713 DOI: 10.1042/0264-6021:3460827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
438 Deng QJ, Yu JP, Liu F, Qi YL, Liu SQ, Yu HG. Relationship between PTEN methylation and its mRNA expression in human gastric cancer cells in vitroShijie Huaren Xiaohua Zazhi 2005; 13(20): 2476-2480 [DOI: 10.11569/wcjd.v13.i20.2476] [Reference Citation Analysis]
439 Murakami Y. Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene 2002;21:6936-48. [PMID: 12362275 DOI: 10.1038/sj.onc.1205825] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
440 Unseld M, Chilla A, Pausz C, Mawas R, Breuss J, Zielinski C, Schabbauer G, Prager GW. PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis. Thromb Haemost 2015;114:379-89. [PMID: 25925849 DOI: 10.1160/TH15-01-0016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
441 Kim JS, Peng X, De PK, Geahlen RL, Durden DL. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood 2002;99:694-7. [PMID: 11781256 DOI: 10.1182/blood.v99.2.694] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
442 Song H, Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem Biophys Res Commun. 2002;299:291-298. [PMID: 12437985 DOI: 10.1016/s0006-291x(02)02551-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
443 Deng L, Zhai X, Liang P, Cui H. Overcoming TRAIL Resistance for Glioblastoma Treatment. Biomolecules 2021;11:572. [PMID: 33919846 DOI: 10.3390/biom11040572] [Reference Citation Analysis]
444 Guo CY, Xu XF, Wu JY, Liu SF. PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 2008; 14(24): 3804-3811 [PMID: 18609703 DOI: 10.3748/wjg.14.3804] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
445 Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:18443-8. [PMID: 16339315 DOI: 10.1073/pnas.0508988102] [Cited by in Crossref: 247] [Cited by in F6Publishing: 241] [Article Influence: 14.5] [Reference Citation Analysis]
446 Guirouilh-Barbat JK, Wilhelm T, Lopez BS. AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget 2010;1:691-9. [PMID: 21321378 DOI: 10.18632/oncotarget.101202] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
447 Zhong T, Zhou J, Zhan S, Wang L, Niu L, Guo J, Li L, Zhang H. Molecular Characteristics, Phylogeny and Expression Profile of the PTEN Gene in Goats. Biochem Genet 2020;58:399-411. [PMID: 32020391 DOI: 10.1007/s10528-020-09947-0] [Reference Citation Analysis]
448 Zheng HC, Sun JM, Li XH, Yang XF, Zhang YC, Xin Y. Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma. Pathol Int. 2003;53:659-666. [PMID: 14516315 DOI: 10.1046/j.1440-1827.2003.01542.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
449 Assis LV, Isoldi MC. Overview of the biochemical and genetic processes in malignant mesothelioma. J Bras Pneumol 2014;40:429-42. [PMID: 25210967 DOI: 10.1590/s1806-37132014000400012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
450 Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008;454:776-779. [PMID: 18594509 DOI: 10.1038/nature07091] [Cited by in Crossref: 520] [Cited by in F6Publishing: 488] [Article Influence: 37.1] [Reference Citation Analysis]
451 Tian Y, Guo W. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Med Sci Monit 2020;26:e920957. [PMID: 32273491 DOI: 10.12659/MSM.920957] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
452 Feng DD, Cai W, Chen X. The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener 2015;4:20. [PMID: 26504519 DOI: 10.1186/s40035-015-0043-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
453 Taylor GS, Dixon JE. PTEN and myotubularins: families of phosphoinositide phosphatases. Methods Enzymol 2003;366:43-56. [PMID: 14674238 DOI: 10.1016/s0076-6879(03)66004-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
454 Chow LM, Baker SJ. Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget 2012;3:67-77. [PMID: 22287481 DOI: 10.18632/oncotarget.425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
455 Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559-70. [PMID: 12894244 DOI: 10.1038/nrc1145] [Cited by in Crossref: 196] [Cited by in F6Publishing: 163] [Article Influence: 10.3] [Reference Citation Analysis]
456 Zhang DD, Guo L, Wang Q. Relationship among PTEN, matrix metalloproteinase-9, and Caspase-3 Expression in gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2006; 14(15): 1487-1492 [DOI: 10.11569/wcjd.v14.i15.1487] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
457 Meric-Bernstam F, Esteva FJ. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. Clin Breast Cancer 2005;6:357-60. [PMID: 16277888 DOI: 10.3816/CBC.2005.n.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
458 Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004;10:8351-6. [PMID: 15623612 DOI: 10.1158/1078-0432.CCR-04-0130] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
459 Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 2010;49:342-52. [PMID: 20073072 DOI: 10.1002/gcc.20746] [Cited by in Crossref: 9] [Cited by in F6Publishing: 43] [Article Influence: 0.8] [Reference Citation Analysis]
460 Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2014;33:1181-1189. [PMID: 23474761 DOI: 10.1038/onc.2013.42] [Cited by in Crossref: 141] [Cited by in F6Publishing: 154] [Article Influence: 15.7] [Reference Citation Analysis]
461 Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 2002;9:24-36. [PMID: 11756757 DOI: 10.1097/00125480-200201000-00004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
462 Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboué B, Latham WC, Eng C, Mulligan LM, Longy M. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 1999;79:718-23. [PMID: 10070859 DOI: 10.1038/sj.bjc.6690115] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 3.2] [Reference Citation Analysis]
463 Kook S, Hoon Kim D, Ryeol Shim S, Kim W, Chun J, Song WK. Caspase-dependent cleavage of tensin induces disruption of actin cytoskeleton during apoptosis. Biochemical and Biophysical Research Communications 2003;303:37-45. [DOI: 10.1016/s0006-291x(03)00280-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
464 Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol 2009;3:39-52. [PMID: 19777070 DOI: 10.4137/cmo.s1008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 57] [Article Influence: 1.2] [Reference Citation Analysis]
465 Backman S, Stambolic V, Mak T. PTEN function in mammalian cell size regulation. Curr Opin Neurobiol 2002;12:516-22. [PMID: 12367630 DOI: 10.1016/s0959-4388(02)00354-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
466 Moon YW, Weil RJ, Pack SD, Park WS, Pak E, Pham T, Karkera JD, Kim HK, Vortmeyer AO, Fuller BG, Zhuang Z. Missense mutation of the MET gene detected in human glioma. Mod Pathol 2000;13:973-7. [PMID: 11007037 DOI: 10.1038/modpathol.3880177] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
467 Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007;8:255-67. [DOI: 10.1007/s11154-007-9038-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 4.1] [Reference Citation Analysis]
468 Cai B, Yang L, Do Jung Y, Zhang Y, Liu X, Zhao P, Li J, Carvalho VF. PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases. Oxidative Medicine and Cellular Longevity 2022;2022:1-26. [DOI: 10.1155/2022/4512503] [Reference Citation Analysis]
469 Nguyen Huu T, Park J, Zhang Y, Park I, Yoon HJ, Woo HA, Lee SR. Redox Regulation of PTEN by Peroxiredoxins. Antioxidants (Basel) 2021;10:302. [PMID: 33669370 DOI: 10.3390/antiox10020302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
470 Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev. 2013;93:1019-1137. [PMID: 23899561 DOI: 10.1152/physrev.00028.2012] [Cited by in Crossref: 875] [Cited by in F6Publishing: 790] [Article Influence: 97.2] [Reference Citation Analysis]
471 Leslie NR, Longy M. Inherited PTEN mutations and the prediction of phenotype. Seminars in Cell & Developmental Biology 2016;52:30-8. [DOI: 10.1016/j.semcdb.2016.01.030] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
472 Tanriover G, Demir N, Pestereli E, Demir R, Kayisli UA. PTEN-mediated Akt activation in human neocortex during prenatal development. Histochem Cell Biol 2005;123:393-406. [DOI: 10.1007/s00418-005-0783-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
473 Saavedra L, Catarino R, Heinz T, Heilmann I, Bezanilla M, Malhó R. Phosphatase and Tensin Homolog Is a Growth Repressor of Both Rhizoid and Gametophore Development in the Moss Physcomitrella patens. Plant Physiol 2015;169:2572-86. [PMID: 26463087 DOI: 10.1104/pp.15.01197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
474 Mao JH, To MD, Perez-Losada J, Wu D, Del Rosario R, Balmain A. Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev 2004;18:1800-5. [PMID: 15289454 DOI: 10.1101/gad.1213804] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
475 Lusche DF, Wessels D, Richardson NA, Russell KB, Hanson BM, Soll BA, Lin BH, Soll DR. PTEN redundancy: overexpressing lpten, a homolog of Dictyostelium discoideum ptenA, the ortholog of human PTEN, rescues all behavioral defects of the mutant ptenA-. PLoS One 2014;9:e108495. [PMID: 25247494 DOI: 10.1371/journal.pone.0108495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
476 Collins VP. Progression as exemplified by human astrocytic tumors. Semin Cancer Biol 1999;9:267-76. [PMID: 10448114 DOI: 10.1006/scbi.1999.0132] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
477 Nguyen KT, Tajmir P, Lin CH, Liadis N, Zhu XD, Eweida M, Tolasa-Karaman G, Cai F, Wang R, Kitamura T, Belsham DD, Wheeler MB, Suzuki A, Mak TW, Woo M. Essential role of Pten in body size determination and pancreatic beta-cell homeostasis in vivo. Mol Cell Biol 2006;26:4511-8. [PMID: 16738317 DOI: 10.1128/MCB.00238-06] [Cited by in Crossref: 71] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
478 Prasad CP, Mohapatra P, Andersson T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers (Basel) 2015;7:1900-24. [PMID: 26393652 DOI: 10.3390/cancers7030868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
479 Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998;19:348-355. [PMID: 9697695 DOI: 10.1038/1235] [Cited by in Crossref: 1055] [Cited by in F6Publishing: 1025] [Article Influence: 44.0] [Reference Citation Analysis]
480 Barré B, Avril S, Coqueret O. Opposite Regulation of Myc and p21 Transcription by STAT3 Proteins. Journal of Biological Chemistry 2003;278:2990-6. [DOI: 10.1074/jbc.m210422200] [Cited by in Crossref: 92] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
481 Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA. 1997;94:9052-9057. [PMID: 9256433 DOI: 10.1073/pnas.94.17.9052] [Cited by in Crossref: 526] [Cited by in F6Publishing: 526] [Article Influence: 21.0] [Reference Citation Analysis]
482 Shi Y, Liu X, Han EK, Guan R, Shoemaker AR, Oleksijew A, Woods KW, Fisher JP, Klinghofer V, Lasko L, McGonigal T, Li Q, Rosenberg SH, Giranda VL, Luo Y. Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia 2005;7:992-1000. [PMID: 16331885 DOI: 10.1593/neo.05355] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
483 Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998;95:15587-91. [PMID: 9861013 DOI: 10.1073/pnas.95.26.15587] [Cited by in Crossref: 439] [Cited by in F6Publishing: 424] [Article Influence: 19.1] [Reference Citation Analysis]
484 Ricci R, Komminoth P, Bannwart F, Torhorst J, Wight E, Heitz PU, Caduff RF. PTEN as a Molecular Marker to Distinguish Metastatic From Primary Synchronous Endometrioid Carcinomas of the Ovary and Uterus: . Diagnostic Molecular Pathology 2003;12:71-8. [DOI: 10.1097/00019606-200306000-00002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
485 Wanner M, Celebi JT, Peacocke M. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J Am Acad Dermatol 2001;44:183-7. [PMID: 11174374 DOI: 10.1067/mjd.2001.110390] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
486 Rameh LE, Cantley LC. The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function. Journal of Biological Chemistry 1999;274:8347-50. [DOI: 10.1074/jbc.274.13.8347] [Cited by in Crossref: 720] [Cited by in F6Publishing: 679] [Article Influence: 31.3] [Reference Citation Analysis]
487 Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 2009;174:1869-79. [PMID: 19395652 DOI: 10.2353/ajpath.2009.080055] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
488 Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010;29:5545-55. [PMID: 20697348 DOI: 10.1038/onc.2010.323] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
489 Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer. 2003;2:23. [PMID: 12740039 DOI: 10.1186/1476-4598-2-23] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 6.3] [Reference Citation Analysis]
490 Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999;96:2110-2115. [PMID: 10051603 DOI: 10.1073/pnas.96.5.2110] [Cited by in Crossref: 410] [Cited by in F6Publishing: 404] [Article Influence: 17.8] [Reference Citation Analysis]
491 Naderali E, Khaki AA, Rad JS, Ali-Hemmati A, Rahmati M, Charoudeh HN. Regulation and modulation of PTEN activity. Mol Biol Rep 2018;45:2869-81. [PMID: 30145641 DOI: 10.1007/s11033-018-4321-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
492 Tsai C, Wu JC, Fang C, Chang AY. PTEN, a negative regulator of PI3K/Akt signaling, sustains brain stem cardiovascular regulation during mevinphos intoxication. Neuropharmacology 2017;123:175-85. [DOI: 10.1016/j.neuropharm.2017.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
493 Asaoka Y, Ikenoue T, Koike K. New targeted therapies for gastric cancer. Expert Opin Investig Drugs 2011;20:595-604. [PMID: 21406037 DOI: 10.1517/13543784.2011.566863] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
494 Milella M, Ciuffreda L, Bria E. Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. In: Reddy LH, Couvreur P, editors. Macromolecular Anticancer Therapeutics. New York: Springer; 2010. pp. 37-83. [DOI: 10.1007/978-1-4419-0507-9_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
495 Zhang SJ, Endo S, Ichikawa T, Yoshimura J, Onda K, Tanaka R, Washiyama K, Kumanishi T. Rare-type mutations of MMAC1 tumor suppressor gene in human glioma cell lines and their tumors of origin. Jpn J Cancer Res 1999;90:934-41. [PMID: 10551321 DOI: 10.1111/j.1349-7006.1999.tb00838.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
496 Jeuken JW, Nelen MR, Vermeer H, van Staveren WC, Kremer H, van Overbeeke JJ, Boerman RH. PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors. PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet Cytogenet 2000;119:42-7. [PMID: 10812170 DOI: 10.1016/s0165-4608(99)00210-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
497 Kohda T, Asai A, Kuroiwa Y, Kobayashi S, Aisaka K, Nagashima G, Yoshida MC, Kondo Y, Kagiyama N, Kirino T, Kaneko-ishino T, Ishino F. Tumour suppressor activity of human imprinted gene PEG3 in a glioma cell line: Tumor suppressor activity of human PEG3. Genes to Cells 2001;6:237-47. [DOI: 10.1046/j.1365-2443.2001.00412.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
498 Dupont J, Renou JP, Shani M, Hennighausen L, LeRoith D. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest 2002;110:815-25. [PMID: 12235113 DOI: 10.1172/JCI13829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 36] [Article Influence: 0.1] [Reference Citation Analysis]
499 Segel GB, Woodlock TJ, Xu J, Li L, Felgar RE, Ryan DH, Lichtman MA, Wang N. Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype. Blood Cells Mol Dis 2003;30:277-87. [PMID: 12737946 DOI: 10.1016/s1079-9796(03)00035-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
500 Montironi R, Mazzucchelli R, Scarpelli M. Molecular Techniques and Prostate Cancer Diagnostic. European Urology 2003;44:390-400. [DOI: 10.1016/s0302-2838(03)00309-9] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
501 Wu H, Wang S, Weng D, Xing H, Song X, Zhu T, Xia X, Weng Y, Xu G, Meng L, Zhou J, Ma D. Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. Cancer Lett 2008;271:205-14. [PMID: 18662848 DOI: 10.1016/j.canlet.2008.06.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
502 Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao M, Mak T, Fyles A, Liu F. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 2003;104:195-203. [DOI: 10.1002/ijc.10909] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
503 Ali A, Mishra PK, Sharma S, Arora A, Saluja SS. Effects of PTEN gene alteration in patients with gallbladder cancer. Cancer Genet. 2015;208:587-594. [PMID: 26586294 DOI: 10.1016/j.cancergen.2015.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
504 Gil EB, Malone Link E, Liu LX, Johnson CD, Lees JA. Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. Proc Natl Acad Sci U S A 1999;96:2925-30. [PMID: 10077613 DOI: 10.1073/pnas.96.6.2925] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 4.3] [Reference Citation Analysis]
505 Jin H, Sun Y, Wang S, Cheng X. Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells. Int J Mol Sci 2013;14:16040-57. [PMID: 23912239 DOI: 10.3390/ijms140816040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
506 Cantini LP, Meier F, Sondak VK, Smalley KS. The future of targeted therapy approaches in melanoma. Expert Opin Drug Discov 2009;4:445-56. [PMID: 23485043 DOI: 10.1517/17460440902828298] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
507 Kato H, Fujimura M, Kumabe T, Ishioka C, Kanamaru R, Yoshimoto T. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. Journal of Clinical Neuroscience 2004;11:37-41. [DOI: 10.1016/j.jocn.2002.09.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
508 Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007;104:5563-8. [PMID: 17372210 DOI: 10.1073/pnas.0609139104] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 8.9] [Reference Citation Analysis]
509 Seki M, Iwakawa J, Cheng H, Cheng P. p53 and PTEN/MMAC1/TEP1 Gene Therapy of Human Prostate PC-3 Carcinoma Xenograft, Using Transferrin-Facilitated Lipofection Gene Delivery Strategy. Human Gene Therapy 2002;13:761-73. [DOI: 10.1089/104303402317322311] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
510 Shapiro JR. GENETICS OF NERVOUS SYSTEM TUMORS. Hematology/Oncology Clinics of North America 2001;15:961-78. [DOI: 10.1016/s0889-8588(05)70262-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
511 Lutchman M, Pack S, Kim AC, Azim A, Emmert-Buck M, van Huffel C, Zhuang Z, Chishti AH. Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression. Cancer Genet Cytogenet 1999;115:65-9. [PMID: 10565303 DOI: 10.1016/s0165-4608(99)00081-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
512 Vaudin P, Dupont J, Duchêne S, Audouin E, Crochet S, Berri C, Tesseraud S. Phosphatase PTEN in chicken muscle is regulated during ontogenesis. Domest Anim Endocrinol 2006;31:123-40. [PMID: 16307863 DOI: 10.1016/j.domaniend.2005.09.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
513 Eldeeb MA, Esmaili M, Hassan M, Ragheb MA. The Role of PTEN-L in Modulating PINK1-Parkin-Mediated Mitophagy. Neurotox Res 2022. [PMID: 35699891 DOI: 10.1007/s12640-022-00475-w] [Reference Citation Analysis]
514 Norden AD, Drappatz J, Wen PY. Malignant Gliomas in Adults. Neuro-Oncology. Elsevier; 2010. pp. 99-120. [DOI: 10.1016/b978-0-7506-7516-1.00005-0] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
515 Faisal Ahmed S, Marsh DJ, Weremowicz S, Morton CC, Williams DM, Eng C. Balanced translocation of 10q and13q, including the PTEN gene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-Riley-Ruvalcaba syndrome. J Clin Endocrinol Metab 1999;84:4665-70. [PMID: 10599735 DOI: 10.1210/jcem.84.12.6178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
516 Xu R, Banka A, Blake JF, Mitchell IS, Wallace EM, Bencsik JR, Kallan NC, Spencer KL, Gloor SL, Martinson M, Risom T, Gross SD, Morales TH, Wu WI, Vigers GP, Brandhuber BJ, Skelton NJ. Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA. Bioorg Med Chem Lett 2011;21:2335-40. [PMID: 21420856 DOI: 10.1016/j.bmcl.2011.02.098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
517 Rempel SA. MOLECULAR BIOLOGY OF NERVOUS SYSTEM TUMORS. Hematology/Oncology Clinics of North America 2001;15:979-1006. [DOI: 10.1016/s0889-8588(05)70263-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
518 Learoyd D, Twigg S, Zedenius JV, Robinson B. The Molecular Genetics of Endocrine Tumours. Journal of Pediatric Endocrinology and Metabolism 1998;11. [DOI: 10.1515/jpem.1998.11.2.195] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
519 Mao X, Jones TA, Tomlinson I, Rowan AJ, Fedorova LI, Zelenin AV, Mao JI, Gutowski NJ, Noble M, Sheer D. Genetic aberrations in glioblastoma multiforme: translocation of chromosome 10 in an O-2A-like cell line. Br J Cancer 1999;79:724-31. [PMID: 10070860 DOI: 10.1038/sj.bjc.6690116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
520 Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999;18:3754-60. [DOI: 10.1038/sj.onc.1202769] [Cited by in Crossref: 188] [Cited by in F6Publishing: 167] [Article Influence: 8.2] [Reference Citation Analysis]
521 Stambolic V, Mak TW, Woodgett JR. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 1999;18:6094-103. [DOI: 10.1038/sj.onc.1203126] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 4.1] [Reference Citation Analysis]
522 Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005;1059:16-25. [PMID: 16382039 DOI: 10.1196/annals.1339.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
523 He L, Fan C, Kapoor A, Ingram AJ, Rybak AP, Austin RC, Dickhout J, Cutz JC, Scholey J, Tang D. α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat Commun 2011;2:307. [PMID: 21556061 DOI: 10.1038/ncomms1309] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
524 Sehgal A, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, Kohler EP, Aldape HC, Simrell CR, Murphy GP. Application of the differential hybridization of Atlas Human expression arrays technique in the identification of differentially expressed genes in human glioblastoma multiforme tumor tissue. J Surg Oncol 1998;67:234-41. [PMID: 9579370 DOI: 10.1002/(sici)1096-9098(199804)67:4<234::aid-jso5>3.0.co;2-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
525 Raizis AM, Ferguson MM, Robinson BA, Atkinson CH, George PM. Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjögren's syndrome. Mol Pathol 1998;51:339-41. [PMID: 10193515 DOI: 10.1136/mp.51.6.339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
526 Longy M, Coulon V, Duboué B, David A, Larrègue M, Eng C, Amati P, Kraimps JL, Bottani A, Lacombe D, Bonneau D. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J Med Genet 1998;35:886-9. [PMID: 9832032 DOI: 10.1136/jmg.35.11.886] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis]
527 Hill VK, Kim JS, James CD, Waldman T. Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing. PLoS One 2017;12:e0176683. [PMID: 28464039 DOI: 10.1371/journal.pone.0176683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
528 Tzani I, Ivanov IP, Andreev DE, Dmitriev RI, Dean KA, Baranov PV, Atkins JF, Loughran G. Systematic analysis of the PTEN 5' leader identifies a major AUU initiated proteoform. Open Biol 2016;6:150203. [PMID: 27249819 DOI: 10.1098/rsob.150203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
529 Zhang F, Miecznikowski JC, Tritchler DL. Identification of supervised and sparse functional genomic pathways. Stat Appl Genet Mol Biol 2020;19:/j/sagmb. [PMID: 32109224 DOI: 10.1515/sagmb-2018-0026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
530 Hanft VN, Shea CR, Mcnutt NS, Pullitzer D, Horenstein MG, Prieto VG. Expression of CD34 in Sclerotic (“Plywood”) Fibromas: . The American Journal of Dermatopathology 2000;22:17-21. [DOI: 10.1097/00000372-200002000-00003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
531 Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007;28:2321-7. [PMID: 17638924 DOI: 10.1093/carcin/bgm159] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
532 Wee S, Lengauer C, Wiederschain D. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. Current Opinion in Oncology 2008;20:77-82. [DOI: 10.1097/cco.0b013e3282f3111e] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
533 Roschier M, Kuusisto E, Suuronen T, Korhonen P, Kyrylenko S, Salminen A. Insulin-like growth factor binding protein 5 and type-1 insulin-like growth factor receptor are differentially regulated during apoptosis in cerebellar granule cells: IGFBP-5 and IGF1R in neuronal apoptosis. Journal of Neurochemistry 2001;76:11-20. [DOI: 10.1046/j.1471-4159.2001.00002.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
534 Hong T, Yang P, Peck K, Chen JJW, Yang S, Chen Y, Wu C. Profiling the Downstream Genes of Tumor Suppressor PTEN in Lung Cancer Cells by Complementary DNA Microarray. Am J Respir Cell Mol Biol 2000;23:355-63. [DOI: 10.1165/ajrcmb.23.3.4002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
535 Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998;153:1411-23. [PMID: 9811332 DOI: 10.1016/S0002-9440(10)65728-8] [Cited by in Crossref: 89] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
536 Robertson GP, Huang H, Cavenee WK. Identification and Validation of Tumor Suppressor Genes. Molecular Cell Biology Research Communications 1999;2:1-10. [DOI: 10.1006/mcbr.1999.0141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
537 Liu Y, Hao S, Yu L, Gao Z. Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. World J Surg Oncol 2015;13:142. [PMID: 25889578 DOI: 10.1186/s12957-015-0558-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
538 Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J, Swisshelm K, Suchard D, MacLeod PM, Kvinnsland S, Gjertsen BT, Heimdal K, Lubs H, Møller P, King MC. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 1997;61:1254-60. [PMID: 9399897 DOI: 10.1086/301639] [Cited by in Crossref: 177] [Cited by in F6Publishing: 158] [Article Influence: 7.1] [Reference Citation Analysis]
539 Deng H, Wu RL, Zhou HY, Huang X, Chen Y, Liu LJ. Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol 2006; 12(7): 1013-1017 [PMID: 16534839 DOI: 10.3748/wjg.v12.i7.1013] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
540 Ágoston EI, Micsik T, Ács B, Fekete K, Hahn O, Baranyai Z, Dede K, Bodoky G, Bursics A, Kulka J, Krenács T, Győrffy B, Harsányi L, Szász AM. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. Diagn Pathol 2016;11:61. [PMID: 27392434 DOI: 10.1186/s13000-016-0508-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
541 Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000;157:1123-8. [PMID: 11021816 DOI: 10.1016/S0002-9440(10)64627-5] [Cited by in Crossref: 193] [Cited by in F6Publishing: 83] [Article Influence: 8.8] [Reference Citation Analysis]
542 Huo YY, Li G, Duan RF, Gou Q, Fu CL, Hu YC, Song BQ, Yang ZH, Wu DC, Zhou PK. PTEN deletion leads to deregulation of antioxidants and increased oxidative damage in mouse embryonic fibroblasts. Free Radic Biol Med 2008;44:1578-91. [PMID: 18275859 DOI: 10.1016/j.freeradbiomed.2008.01.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
543 Chen J, Lindblom A. Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet 2000;57:394-7. [PMID: 10852375 DOI: 10.1034/j.1399-0004.2000.570511.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
544 Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276:993-998. [PMID: 11035045 DOI: 10.1074/jbc.M009134200] [Cited by in Crossref: 439] [Cited by in F6Publishing: 231] [Article Influence: 20.9] [Reference Citation Analysis]
545 Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA. Multicentric Glioblastoma Multiforme in a Patient with BRCA-1 Invasive Breast Cancer. Breast Journal 2006;12:470-4. [DOI: 10.1111/j.1075-122x.2006.00307.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
546 Huang Z, Wu Y, Zhou X, Qian J, Zhu W, Shu Y, Liu P. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncology 2015;11:1687-99. [DOI: 10.2217/fon.15.70] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
547 Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, Yong R, Murty VV, Asara JM, Cantley LC, Parsons R. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov 2017;7:380-90. [PMID: 28255082 DOI: 10.1158/2159-8290.CD-16-0612] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
548 Pal T, Hamel N, Vesprini D, Sanders K, Mitchell M, Quercia N, Ng Cheong N, Murray A, Foulkes W, Narod SA. Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications. Fam Cancer 2001;1:17-24. [PMID: 14574011 DOI: 10.1023/a:1011541424424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
549 Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem. 1999;263:605-611. [PMID: 10469123 DOI: 10.1046/j.1432-1327.1999.00542.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 4.3] [Reference Citation Analysis]
550 Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res. 1998;26:1396-1400. [PMID: 9490783 DOI: 10.1093/nar/26.6.1396] [Cited by in Crossref: 173] [Cited by in F6Publishing: 158] [Article Influence: 7.2] [Reference Citation Analysis]
551 Smith IN, Briggs JM. Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer. Proteins 2016;84:1625-43. [PMID: 27481051 DOI: 10.1002/prot.25105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
552 Lusche DF, Buchele EC, Russell KB, Soll BA, Vitolo MI, Klemme MR, Wessels DJ, Soll DR. Overexpressing TPTE2 (TPIP), a homolog of the human tumor suppressor gene PTEN, rescues the abnormal phenotype of the PTEN-/- mutant. Oncotarget 2018;9:21100-21. [PMID: 29765523 DOI: 10.18632/oncotarget.24941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
553 Kawana Y, Ichikawa T, Suzuki H, Ueda T, Komiya A, Ichikawa Y, Furuya Y, Akakura K, Igarashi T, Ito H. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. Prostate 2002;53:60-4. [DOI: 10.1002/pros.10131] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
554 Cao Y, Wang H, Yang L, Zhang Z, Li C, Yuan X, Bu L, Chen L, Chen Y, Li CM, Guo D. PTEN-L promotes type I interferon responses and antiviral immunity. Cell Mol Immunol 2018;15:48-57. [PMID: 29057971 DOI: 10.1038/cmi.2017.102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
555 Kim TH, Franco HL, Jung SY, Qin J, Broaddus RR, Lydon JP, Jeong JW. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 2010;29:3770-80. [PMID: 20418913 DOI: 10.1038/onc.2010.126] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
556 Gao M, Wang J, Wang W, Liu J, Wong CW. Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor γ coactivator-1β expression. Br J Pharmacol 2011;162:1000-8. [PMID: 21054343 DOI: 10.1111/j.1476-5381.2010.01105.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
557 Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, Rowley DR, Nelson PS, Moore DD, Yang F. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest 2021;131:135465. [PMID: 33586682 DOI: 10.1172/JCI135465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
558 Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS, Van Meir EG. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000;191:1789-98. [PMID: 10811871 DOI: 10.1084/jem.191.10.1789] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 3.0] [Reference Citation Analysis]
559 Kim SS, Yoo NJ, Jeong EG, Kim MS, Lee SH. Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS. 2008;116:779-784. [PMID: 19024597 DOI: 10.1111/j.1600-0463.2008.00999.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
560 Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43-61. [PMID: 28838947 DOI: 10.1530/JOE-17-0266] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
561 Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001;3:1124-8. [DOI: 10.1038/ncb1201-1124] [Cited by in Crossref: 299] [Cited by in F6Publishing: 285] [Article Influence: 14.2] [Reference Citation Analysis]
562 Senthilkumar K, Elumalai P, Arunkumar R, Banudevi S, Gunadharini ND, Sharmila G, Selvakumar K, Arunakaran J. Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem 2010;344:173-84. [PMID: 20658310 DOI: 10.1007/s11010-010-0540-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
563 Inoue T, Ogawa O. Role of signaling transduction pathways in development of castration-resistant prostate cancer. Prostate Cancer 2011;2011:647987. [PMID: 22110995 DOI: 10.1155/2011/647987] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
564 Gross KL, Morton CC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001;44:335-49. [PMID: 11344997 DOI: 10.1097/00003081-200106000-00020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
565 Toker A. Phosphoinositide 3-kinases-a historical perspective. Subcell Biochem. 2012;58:95-110. [PMID: 22403075 DOI: 10.1007/978-94-007-3012-0_4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
566 Santourlidis S, Warskulat U, Florl AR, Maas S, Pulte T, Fischer J, Müller W, Schulz WA. Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol Carcinog 2001;32:36-43. [PMID: 11568974 DOI: 10.1002/mc.1062] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
567 George Priya Doss C, Rajith B. A New Insight into Structural and Functional Impact of Single-Nucleotide Polymorphisms in PTEN Gene. Cell Biochem Biophys 2013;66:249-63. [DOI: 10.1007/s12013-012-9472-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
568 Liang Z, Tang Y, Li H, Xie Y, Zhan L. Association of phosphatase and tension homologue deleted on chromosome ten polymorphism rs1903858, but not serum levels with the risk of non-small-cell lung cancer: A case-control study. J Clin Lab Anal 2020;34:e23328. [PMID: 32537792 DOI: 10.1002/jcla.23328] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
569 Law JW, Lee AY. The role of semaphorins and their receptors in gliomas. J Signal Transduct 2012;2012:902854. [PMID: 23050142 DOI: 10.1155/2012/902854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
570 Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ. Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 2010;119:157-75. [PMID: 19936768 DOI: 10.1007/s00401-009-0614-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
571 Stambolic V. PTEN: a new twist on beta-catenin? Trends Pharmacol Sci 2002;23:104-6. [PMID: 11879670 DOI: 10.1016/s0165-6147(00)01984-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
572 Wang L, Liu Y, Yan Lu S, Nguyen KT, Schroer SA, Suzuki A, Mak TW, Gaisano H, Woo M. Deletion of Pten in pancreatic ß-cells protects against deficient ß-cell mass and function in mouse models of type 2 diabetes. Diabetes. 2010;59:3117-3126. [PMID: 20852026 DOI: 10.2337/db09-1805] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
573 Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004;75 Suppl 2:ii2-11. [PMID: 15146033 DOI: 10.1136/jnnp.2004.040337] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
574 Goberdhan DC, Paricio N, Goodman EC, Mlodzik M, Wilson C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev 1999;13:3244-58. [PMID: 10617573 DOI: 10.1101/gad.13.24.3244] [Cited by in Crossref: 264] [Cited by in F6Publishing: 257] [Article Influence: 12.0] [Reference Citation Analysis]
575 Li Y, Sun J, Cai Y, Jiang Y, Wang X, Huang X, Yin Y, Li H. MiR-200a acts as an oncogene in colorectal carcinoma by targeting PTEN. Experimental and Molecular Pathology 2016;101:308-13. [DOI: 10.1016/j.yexmp.2016.10.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
576 de Assis LV, Isoldi MC. The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol 2014;35:889-901. [PMID: 24081673 DOI: 10.1007/s13277-013-1210-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
577 Lacroix J, Halaszovich CR, Schreiber DN, Leitner MG, Bezanilla F, Oliver D, Villalba-Galea CA. Controlling the activity of a phosphatase and tensin homolog (PTEN) by membrane potential. J Biol Chem 2011;286:17945-53. [PMID: 21454672 DOI: 10.1074/jbc.M110.201749] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
578 Izumoto S, Ohnishi T, Kanemura H, Arita N, Maruno M, Moriuchi T, Suzuki S, Yoshimine T. PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis. J Neurooncol 2001;53:21-6. [PMID: 11678426 DOI: 10.1023/a:1011839920176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
579 Xiao M, An Y, Wang F, Yao C, Zhang C, Xin J, Duan Y, Zhao X, Fang N, Ji S. A chimeric protein PTEN-L-p53 enters U251 cells to repress proliferation and invasion. Exp Cell Res 2018;369:234-42. [PMID: 29802838 DOI: 10.1016/j.yexcr.2018.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
580 Montagne J. Genetic and Molecular Mechanisms of Cell Size Control. Molecular Cell Biology Research Communications 2000;4:195-202. [DOI: 10.1006/mcbr.2001.0284] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
581 Wang S, Hao H, Deng K, Li Y, Cheng Z, Lv C, Liu Z, Yang J, Pan L. Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration. Leukemia & Lymphoma 2012;53:1162-8. [DOI: 10.3109/10428194.2011.647311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
582 Mizoguchi M, Kuga D, Guan Y, Hata N, Nakamizo A, Yoshimoto K, Sasaki T. Loss of heterozygosity analysis in malignant gliomas. Brain Tumor Pathol. 2011;28:191-196. [PMID: 21629980 DOI: 10.1007/s10014-011-0038-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
583 Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Similarities of cutaneous and breast pathology in Cowden's Syndrome. Exp Dermatol 1998;7:380-90. [PMID: 9858141 DOI: 10.1111/j.1600-0625.1998.tb00338.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
584 Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129-139. [PMID: 17218260 DOI: 10.1016/j.cell.2006.11.039] [Cited by in Crossref: 466] [Cited by in F6Publishing: 457] [Article Influence: 31.1] [Reference Citation Analysis]
585 Patel HS, Kantarjian HM, Bueso-ramos CE, Medeiros LJ, Haidar MA. Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. Genes Chromosom Cancer 2005;42:87-94. [DOI: 10.1002/gcc.20116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
586 Choi D, Nguyen KT, Wang L, Schroer SA, Suzuki A, Mak TW, Woo M. Partial deletion of Pten in the hypothalamus leads to growth defects that cannot be rescued by exogenous growth hormone. Endocrinology 2008;149:4382-6. [PMID: 18499759 DOI: 10.1210/en.2007-1761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
587 Takakura S, Kohno T, Shimizu K, Ohwada S, Okamoto A, Yokota J. Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers. Oncogene 2000;19:836-40. [DOI: 10.1038/sj.onc.1203388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
588 Sun Z, Ji N, Bi M, Wang S, Liu X, Wang Z. PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma. Tumor Biol 2015;36:5849-57. [DOI: 10.1007/s13277-015-3256-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
589 Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A 2011;108:19024-9. [PMID: 22065749 DOI: 10.1073/pnas.1111963108] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 6.7] [Reference Citation Analysis]
590 Groen JN, Capraro D, Morris KV. The emerging role of pseudogene expressed non-coding RNAs in cellular functions. Int J Biochem Cell Biol 2014;54:350-5. [PMID: 24842102 DOI: 10.1016/j.biocel.2014.05.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
591 Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci. 1998;353:583-605. [PMID: 9602534 DOI: 10.1098/rstb.1998.0228] [Cited by in Crossref: 292] [Cited by in F6Publishing: 281] [Article Influence: 12.2] [Reference Citation Analysis]
592 Leighton X, Srikantan V, Pollard HB, Sukumar S, Srivastava M. Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas. Cancer Letters 2004;210:239-44. [DOI: 10.1016/j.canlet.2004.01.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
593 Zundel W, Schindler C, Haas-kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6. [DOI: 10.1101/gad.14.4.391] [Cited by in Crossref: 100] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
594 Mathews MS, Shih EC, Zamora G, Sun CH, Cho SK, Kwon YJ, Hirschberg H. Glioma cell growth inhibition following photochemical internalization enhanced non-viral PTEN gene transfection. Lasers Surg Med 2012;44:746-54. [PMID: 23018764 DOI: 10.1002/lsm.22082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
595 Bussaglia E, Pujol RM, Jesus Gil M, Martí RM, Tuneu A, Febrer MI, Garcia-patos V, Ruiz EM, Barnadas M, Alegre M, Serrano S, Matias-guiu X. PTEN Mutations in Eight Spanish Families and One Brazilian Family with Cowden Syndrome. Journal of Investigative Dermatology 2002;118:639-44. [DOI: 10.1046/j.1523-1747.2002.01728.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
596 Zhu Y, Zhang X, Wang L, Ji Z, Xie M, Zhou X, Liu Z, Shi H, Yu R. Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling. J Cell Mol Med 2017;21:2685-94. [PMID: 28470949 DOI: 10.1111/jcmm.13184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
597 Yang Z, Cao X, Xu W, Xie C, Chen J, Zhu Y, Lu N. Phosphorylation of phosphatase and tensin homolog induced by Helicobacter pylori promotes cell invasion by activation of focal adhesion kinase. Oncol Lett 2018;15:1051-7. [PMID: 29399165 DOI: 10.3892/ol.2017.7430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
598 Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011;17:512-27. [PMID: 22157296 DOI: 10.1097/PPO.0b013e31823e701a] [Cited by in Crossref: 69] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
599 Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW, Min YH. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 2003;122:454-6. [PMID: 12877673 DOI: 10.1046/j.1365-2141.2003.04452.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.3] [Reference Citation Analysis]
600 Kim J, Lee S, Kim H, Lee H, Seong KM, Youn H, Youn B. Autophagic Organelles in DNA Damage Response. Front Cell Dev Biol 2021;9:668735. [PMID: 33912571 DOI: 10.3389/fcell.2021.668735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
601 Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK. Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Transl Oncol 2012;5:422-9. [PMID: 23323157 DOI: 10.1593/tlo.12241] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
602 Bartholow TL, Becich MJ, Chandran UR, Parwani AV. Immunohistochemical analysis of ezrin-radixin-moesin-binding phosphoprotein 50 in prostatic adenocarcinoma. BMC Urol. 2011;11:12. [PMID: 21672215 DOI: 10.1186/1471-2490-11-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
603 Chen Q, Samaranayake L, Zhou H, Xiao L. Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma. Oral Oncology 2000;36:95-9. [DOI: 10.1016/s1368-8375(99)00068-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
604 Bove B, Dunbrack R, Godwin A. BRCA-1, BRCA-2 and Hereditary Breast Cancer. In: Pasqualini J, editor. Breast Cancer. CRC Press; 2002. pp. 555-624. [DOI: 10.1201/b14039-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
605 Zhang M, Zhang X. The role of PI3K/AKT/FOXO signaling in psoriasis. Arch Dermatol Res 2019;311:83-91. [PMID: 30483877 DOI: 10.1007/s00403-018-1879-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
606 Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2007;31:673-82. [PMID: 17007924 DOI: 10.1016/j.leukres.2006.08.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 4.4] [Reference Citation Analysis]
607 Xu X, Chen G, Wu L, Liu L. Association of genetic polymorphisms in PTEN and additional gene-gene interaction with risk of esophageal squamous cell carcinoma in Chinese Han population. Dis Esophagus 2016;29:944-9. [PMID: 26541596 DOI: 10.1111/dote.12428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
608 Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H, Hla T. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A 2005;102:4312-7. [PMID: 15764699 DOI: 10.1073/pnas.0409784102] [Cited by in Crossref: 120] [Cited by in F6Publishing: 118] [Article Influence: 7.1] [Reference Citation Analysis]
609 Mayo LD, Seo YR, Jackson MW, Smith ML, Guzman JR, Korgaonkar CK, Donner DB. Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified. Journal of Biological Chemistry 2005;280:25953-9. [DOI: 10.1074/jbc.m503026200] [Cited by in Crossref: 104] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
610 Puxeddu E, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutat Res 2005;570:17-32. [PMID: 15680400 DOI: 10.1016/j.mrfmmm.2004.09.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
611 Wu CY, Lin MW, Wu DC, Huang YB, Huang HT, Chen CL. The role of phosphoinositide-regulated actin reorganization in chemotaxis and cell migration. Br J Pharmacol 2014;171:5541-54. [PMID: 25420930 DOI: 10.1111/bph.12777] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
612 Ma J, Guo X, Zhang J, Wu D, Hu X, Li J, Lan Q, Liu Y, Dong W. PTEN Gene Induces Cell Invasion and Migration via Regulating AKT/GSK-3β/β-Catenin Signaling Pathway in Human Gastric Cancer. Dig Dis Sci 2017;62:3415-25. [PMID: 29030742 DOI: 10.1007/s10620-017-4764-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
613 Li G, Robinson GW, Lesche R, Martinez-diaz H, Jiang Z, Rozengurt N, Wagner K, Wu D, Lane TF, Liu X, Hennighausen L, Wu H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002;129:4159-70. [DOI: 10.1242/dev.129.17.4159] [Cited by in Crossref: 73] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
614 Goberdhan DC, Wilson C. PTEN: tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet. 2003;12 Spec No 2:R239-R248. [PMID: 12928488 DOI: 10.1093/hmg/ddg288] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.3] [Reference Citation Analysis]
615 Lee H, Srinivas H, Xia D, Lu Y, Superty R, Lapushin R, Gomez-manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival. Journal of Biological Chemistry 2003;278:23630-8. [DOI: 10.1074/jbc.m300997200] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
616 van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, de Krijger RR. PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol 2006;209:274-80. [PMID: 16538614 DOI: 10.1002/path.1968] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
617 Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, Lasky LA. Interaction of the Tumor Suppressor PTEN/MMAC with a PDZ Domain of MAGI3, a Novel Membrane-associated Guanylate Kinase. Journal of Biological Chemistry 2000;275:21477-85. [DOI: 10.1074/jbc.m909741199] [Cited by in Crossref: 190] [Cited by in F6Publishing: 74] [Article Influence: 8.6] [Reference Citation Analysis]
618 Pineau P, Marchio A, Nagamori S, Seki S, Tiollais P, Dejean A. Homozygous deletion scanning in hepatobiliary tumor cell lines reveals alternative pathways for liver carcinogenesis. Hepatology 2003;37:852-61. [PMID: 12668978 DOI: 10.1053/jhep.2003.50138] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
619 Zhao Y, Zheng R, Li J, Lin F, Liu L. Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis. Thorac Cancer 2017;8:203-13. [PMID: 28263037 DOI: 10.1111/1759-7714.12425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
620 Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJ. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 1998;79:159-65. [PMID: 9583731 DOI: 10.1002/(sici)1097-0215(19980417)79:2<159::aid-ijc11>3.0.co;2-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
621 Gao F, Al-Azayzih A, Somanath PR. Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis. Oncotarget 2015;6:5947-62. [PMID: 25714023 DOI: 10.18632/oncotarget.3335] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
622 Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer 2010;1:409-20. [PMID: 20827424 DOI: 10.1177/1947601910373795] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 7.5] [Reference Citation Analysis]
623 Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 2008;7:1151-6. [PMID: 18418043 DOI: 10.4161/cc.7.9.5817] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
624 Mentel M, Laketa V, Subramanian D, Gillandt H, Schultz C. Photoactivatable and Cell-Membrane-Permeable Phosphatidylinositol 3,4,5-Trisphosphate. Angew Chem Int Ed 2011;50:3811-4. [DOI: 10.1002/anie.201007796] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
625 Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27. [PMID: 14695335 DOI: 10.1016/S0002-9440(10)63112-4] [Cited by in Crossref: 420] [Cited by in F6Publishing: 214] [Article Influence: 23.3] [Reference Citation Analysis]
626 Wishart MJ, Taylor GS, Slama JT, Dixon JE. PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench. Curr Opin Cell Biol 2001;13:172-81. [PMID: 11248551 DOI: 10.1016/s0955-0674(00)00195-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
627 Kros JM, van Run PRWA, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJJ, van Dekken H. Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). J Pathol 1999;188:282-8. [DOI: 10.1002/(sici)1096-9896(199907)188:3<282::aid-path355>3.0.co;2-s] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
628 Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37-47. [PMID: 1964473 DOI: 10.1038/nrd2926] [Cited by in Crossref: 1691] [Cited by in F6Publishing: 1605] [Article Influence: 54.5] [Reference Citation Analysis]
629 Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G, Morotti A. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. PLoS One 2014;9:e110682. [PMID: 25343485 DOI: 10.1371/journal.pone.0110682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
630 Castellano-Sanchez AA, Ohgaki H, Yokoo H, Scheithauer BW, Burger PC, Hamilton RL, Finkelstein SD, Brat DJ. Granular cell astrocytomas show a high frequency of allelic loss but are not a genetically defined subset. Brain Pathol 2003;13:185-94. [PMID: 12744472 DOI: 10.1111/j.1750-3639.2003.tb00018.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
631 Wong JT, Kim PT, Peacock JW, Yau TY, Mui AL, Chung SW, Sossi V, Doudet D, Green D, Ruth TJ, Parsons R, Verchere CB, Ong CJ. Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia 2007;50:395-403. [PMID: 17195063 DOI: 10.1007/s00125-006-0531-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
632 Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, Chinault AC. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 2001;20:6707-17. [PMID: 11709705 DOI: 10.1038/sj.onc.1204866] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
633 Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends Biochem Sci 2014;39:183-90. [PMID: 24656806 DOI: 10.1016/j.tibs.2014.02.006] [Cited by in Crossref: 155] [Cited by in F6Publishing: 153] [Article Influence: 19.4] [Reference Citation Analysis]
634 Song Z, Han X, Shen L, Zou H, Zhang B, Liu J, Gong A. PTEN silencing enhances neuronal proliferation and differentiation by activating PI3K/Akt/GSK3β pathway in vitro. Exp Cell Res 2018;363:179-87. [PMID: 29305963 DOI: 10.1016/j.yexcr.2018.01.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
635 Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation: PI3k-Akt Signalling in Cervical Cancer. Int J Cancer 2006;118:1877-83. [DOI: 10.1002/ijc.21461] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 6.6] [Reference Citation Analysis]
636 Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001;276:48627-48630. [PMID: 11707428 DOI: 10.1074/jbc.C100556200] [Cited by in Crossref: 302] [Cited by in F6Publishing: 149] [Article Influence: 14.4] [Reference Citation Analysis]
637 Palmieri G, Manca A, Cossu A, Ruiu G, Pisano M, Cherchi P, Dessole S, Pintus A, Massarelli G, Tanda F, Pirastu M. Microsatellite analysis at 10q25-q26 in Sardinian patients with sporadic endometrial carcinoma: Identification of specific patterns of genetic alteration. Cancer 2000;89:1773-82. [DOI: 10.1002/1097-0142(20001015)89:8<1773::aid-cncr18>3.0.co;2-h] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
638 Yu WP, Pallen CJ, Tay A, Jirik FR, Brenner S, Tan YH, Venkatesh B. Conserved synteny between the Fugu and human PTEN locus and the evolutionary conservation of vertebrate PTEN function. Oncogene 2001;20:5554-61. [PMID: 11571655 DOI: 10.1038/sj.onc.1204679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
639 Gbelcová H, Bakeš P, Priščáková P, Šišovský V, Hojsíková I, Straka Ľ, Konečný M, Markus J, D'Acunto CW, Ruml T, Böhmer D, Danihel Ľ, Repiská V. PTEN sequence analysis in endometrial hyperplasia and endometrial carcinoma in Slovak women. Anal Cell Pathol (Amst) 2015;2015:746856. [PMID: 26114084 DOI: 10.1155/2015/746856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
640 Chen P, Hutter D, Liu P, Liu Y. A mammalian expression system for rapid production and purification of active MAP kinase phosphatases. Protein Expr Purif 2002;24:481-8. [PMID: 11922765 DOI: 10.1006/prep.2001.1599] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
641 Huntoon K, Toland AMS, Dahiya S. Meningioma: A Review of Clinicopathological and Molecular Aspects. Front Oncol 2020;10:579599. [PMID: 33194703 DOI: 10.3389/fonc.2020.579599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
642 Breuksch I, Welter J, Bauer HK, Enklaar T, Frees S, Thüroff JW, Hasenburg A, Prawitt D, Brenner W. In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself. Cell Commun Signal 2018;16:35. [PMID: 29954386 DOI: 10.1186/s12964-018-0247-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
643 Maxwell, Risinger, Shaw, Alvarez, Barrett, Futreal, Berchuck. Mutations in the PTEN tumor suppressor gene in cervical carcinomas. Int J Gynecol Cancer 1998;8:489-93. [DOI: 10.1046/j.1525-1438.1998.98102.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
644 Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam Horm. 2004;67:409-426. [PMID: 15110188 DOI: 10.1016/s0083-6729(04)67021-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
645 Bai Y, Zhang QG, Wang XH. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome. Eur J Med Res 2014;19:66. [PMID: 25498217 DOI: 10.1186/s40001-014-0066-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
646 Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010;120:681-93. [PMID: 20197621 DOI: 10.1172/JCI40535] [Cited by in Crossref: 217] [Cited by in F6Publishing: 155] [Article Influence: 18.1] [Reference Citation Analysis]
647 Thaker NG, Pollack IF. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 2009;9:1815-36. [PMID: 19951140 DOI: 10.1586/ern.09.116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
648 Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S, Koeffler HP, Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005;96:425-33. [PMID: 16053514 DOI: 10.1111/j.1349-7006.2005.00063.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
649 Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M. PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations. Int J Cancer 2003;104:175-8. [PMID: 12569572 DOI: 10.1002/ijc.10918] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
650 Luo JH, Liu S, Tao J, Ren BG, Luo K, Chen ZH, Nalesnik M, Cieply K, Ma T, Cheng SY, Chen Q, Michalopoulos GK, Nelson JB, Bhargava R, Zhang J, Ma D, Jarrard D, Pennathur A, Luketich JD, DeFranco DB, Monga SP, Tseng G, Yu YP. Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. Oncogene 2021;40:1064-76. [PMID: 33323972 DOI: 10.1038/s41388-020-01582-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
651 Fukumoto M, Ijuin T, Takenawa T. PI(3,4)P2 plays critical roles in the regulation of focal adhesion dynamics of MDA-MB-231 breast cancer cells. Cancer Sci 2017;108:941-51. [PMID: 28247964 DOI: 10.1111/cas.13215] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
652 Boardman LA. Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am. 2002;31:1107-1131. [PMID: 12489281 DOI: 10.1016/s0889-8553(02)00049-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
653 Zhang D, Fan F, Yang J, Wang X, Qiu D, Jiang L. FgTep1p is linked to the phosphatidylinositol-3 kinase signalling pathway and plays a role in the virulence of Fusarium graminearum on wheat. Mol Plant Pathol 2010;11:495-502. [PMID: 20618707 DOI: 10.1111/j.1364-3703.2010.00626.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
654 Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol 2017;39:101042831770575. [DOI: 10.1177/1010428317705754] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
655 Guo J, Zhu T, Xiao ZX, Chen CY. Modulation of intracellular signaling pathways to induce apoptosis in prostate cancer cells. J Biol Chem 2007;282:24364-72. [PMID: 17573344 DOI: 10.1074/jbc.M702938200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
656 Kim MK. Novel insight into the function of tankyrase. Oncol Lett 2018;16:6895-902. [PMID: 30546421 DOI: 10.3892/ol.2018.9551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
657 Albitar L, Carter MB, Davies S, Leslie KK. Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer. Gynecologic Oncology 2007;106:94-104. [DOI: 10.1016/j.ygyno.2007.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
658 Wierling C, Kühn A, Hache H, Daskalaki A, Maschke-Dutz E, Peycheva S, Li J, Herwig R, Lehrach H. Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment. Mutat Res 2012;746:163-70. [PMID: 22285941 DOI: 10.1016/j.mrgentox.2012.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
659 Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006;30:262-5. [PMID: 16112193 DOI: 10.1016/j.leukres.2005.07.008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
660 Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer. 2010;1:1170-1177. [PMID: 21779440 DOI: 10.1177/1947601911407325] [Cited by in Crossref: 230] [Cited by in F6Publishing: 223] [Article Influence: 20.9] [Reference Citation Analysis]
661 Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer 2001;84:748-53. [PMID: 11259087 DOI: 10.1054/bjoc.2000.1660] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
662 Willsey AJ, State MW. Autism spectrum disorders: from genes to neurobiology. Curr Opin Neurobiol 2015;30:92-9. [PMID: 25464374 DOI: 10.1016/j.conb.2014.10.015] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 12.5] [Reference Citation Analysis]
663 Sehgal A. Molecular changes during the genesis of human gliomas. Semin Surg Oncol 1998;14:3-12. [DOI: 10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
664 Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009;15:304-14. [PMID: 19345329 DOI: 10.1016/j.ccr.2009.02.012] [Cited by in Crossref: 134] [Cited by in F6Publishing: 127] [Article Influence: 10.3] [Reference Citation Analysis]
665 Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005;7:193-204. [PMID: 15710331 DOI: 10.1016/j.ccr.2005.01.009] [Cited by in Crossref: 242] [Cited by in F6Publishing: 216] [Article Influence: 14.2] [Reference Citation Analysis]
666 Muresu R, Sini M, Cossu A, Tore S, Baldinu P, Manca A, Pisano M, Loddo C, Dessole S, Pintus A, Tanda F, Palmieri G. Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. European Journal of Cancer 2002;38:1802-9. [DOI: 10.1016/s0959-8049(02)00152-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
667 Luan S. Protein phosphatases: Structure, regulation, and function. Elsevier; 2000. pp. 67-107. [DOI: 10.1016/s0065-2296(00)32022-5] [Cited by in Crossref: 19] [Article Influence: 0.9] [Reference Citation Analysis]
668 Heymont J, Berenfeld L, Collins J, Kaganovich A, Maynes B, Moulin A, Ratskovskaya I, Poon PP, Johnston GC, Kamenetsky M, DeSilva J, Sun H, Petsko GA, Engebrecht J. TEP1, the yeast homolog of the human tumor suppressor gene PTEN/MMAC1/TEP1, is linked to the phosphatidylinositol pathway and plays a role in the developmental process of sporulation. Proc Natl Acad Sci U S A 2000;97:12672-7. [PMID: 11070083 DOI: 10.1073/pnas.97.23.12672] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
669 Wishart MJ, Dixon JE. Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends in Biochemical Sciences 1998;23:301-6. [DOI: 10.1016/s0968-0004(98)01241-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
670 Mizuno Y, Hattori N, Mochizuki H. Genetic aspects of Parkinson's disease. Handb Clin Neurol 2007;83:217-44. [PMID: 18808916 DOI: 10.1016/S0072-9752(07)83009-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
671 Karayi MK, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7:6-20. [PMID: 14999233 DOI: 10.1038/sj.pcan.4500697] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
672 Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761-769. [PMID: 23619167 DOI: 10.1158/2159-8290.cd-13-0103] [Cited by in Crossref: 384] [Cited by in F6Publishing: 242] [Article Influence: 42.7] [Reference Citation Analysis]
673 Chang J, Chen Y, Perng L, Wang N, Kao M, Yang T, Chang C, Tsai C. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. European Journal of Cancer 1999;35:647-51. [DOI: 10.1016/s0959-8049(98)00411-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
674 Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T. Sample type bias in the analysis of cancer genomes. Cancer Res 2009;69:5630-3. [PMID: 19567670 DOI: 10.1158/0008-5472.CAN-09-1055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
675 Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008;27:5477-5485. [PMID: 18794882 DOI: 10.1038/onc.2008.248] [Cited by in Crossref: 250] [Cited by in F6Publishing: 234] [Article Influence: 17.9] [Reference Citation Analysis]
676 Cvrčková F. Formins: emerging players in the dynamic plant cell cortex. Scientifica (Cairo) 2012;2012:712605. [PMID: 24278734 DOI: 10.6064/2012/712605] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
677 Mcconkey DJ, Bondar V. Regulation and Function of Detachment-Induced Cell Death (Anoikis) in Cancer Progression and Metastasis. In: Gewirtz DA, Holt SE, Grant S, editors. Apoptosis, Senescence, and Cancer. Totowa: Humana Press; 2007. pp. 109-22. [DOI: 10.1007/978-1-59745-221-2_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
678 Wu SK, Wang BJ, Yang Y, Feng XH, Zhao XP, Yang DL. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol 2007; 13(34): 4554-4559 [PMID: 17729405 DOI: 10.3748/wjg.v13.i34.4554] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
679 Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN Gene Alterations in Lymphoid Neoplasms. Blood 1998;92:3410-5. [DOI: 10.1182/blood.v92.9.3410] [Cited by in Crossref: 117] [Article Influence: 4.9] [Reference Citation Analysis]
680 Iwasa K, Hayashi S, Fujishiro T, Kanzaki N, Hashimoto S, Sakata S, Chinzei N, Nishiyama T, Kuroda R, Kurosaka M. PTEN regulates matrix synthesis in adult human chondrocytes under oxidative stress: MATRIX SYNTHESIS IN ADULT HUMAN CHONDROCYTES. J Orthop Res 2014;32:231-7. [DOI: 10.1002/jor.22506] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
681 Wang Q, Wei Y, Mottamal M, Roberts MF, Krilov G. Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain. J Mol Graph Model 2010;29:102-14. [PMID: 20538496 DOI: 10.1016/j.jmgm.2010.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
682 Grønbæk K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-jensen K, Guldberg P. Somatic Fas Mutations in Non-Hodgkin’s Lymphoma: Association With Extranodal Disease and Autoimmunity. Blood 1998;92:3018-24. [DOI: 10.1182/blood.v92.9.3018.421k52_3018_3024] [Cited by in Crossref: 16] [Article Influence: 0.7] [Reference Citation Analysis]
683 Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J. PTEN reconstitution alters glioma responses to c-Met pathway inhibition. Anticancer Drugs 2011;22:905-12. [PMID: 21654317 DOI: 10.1097/CAD.0b013e3283484750] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]